Safe approaches for camptothecin delivery: Structural analogues and nanomedicines by BOTELLA ASUNCION, PABLO & Rivero-Buceta, Eva María
 Document downloaded from: 
 

























Botella Asuncion, P.; Rivero-Buceta, EM. (2017). Safe approaches for camptothecin




Safe approaches for camptothecin delivery: structural analogues and 
nanomedicines 
Pablo Botella * and Eva Rivero-Buceta 
Instituto de Tecnología Química, Universitat Politècnica de València-Consejo Superior de 
Investigaciones Científicas, Avenida de los Naranjos s/n, 46022 Valencia, Spain 
 









Twenty-(S)-Camptothecin is a strongly cytotoxic molecule with excellent antitumor 
activity over a wide spectrum of human cancers. However, the direct formulation is 
limited by its poor water solubility, low plasmatic stability and severe toxicity, which 
currently limits its clinical use. As a consequence, two strategies have been developed 
in order to achieve safe and efficient delivery of camptothecin to target cells: structural 
analogues and nanomedicines. In this review we summarize recent advances in the 
design, synthesis and development of camptothecin molecular derivatives and 
supramolecular vehicles, following a systematic classification according to structure-
activity reationships (structural analogues) or chemical nature (nanomedicines). A series 
of organic, inorganic and hybrid materials are presented as nanoplatforms to overcome 
camptothecin restrictions in administration, biodistribution, pharmacokinetics and 
toxicity. Nanocarriers which respond to a variety of stimuli endogenously (e.g., pH, redox 
potential, enzyme activity) or exogenously (e.g., magnetic field, light, temperature, 
ultrasound) seem the best positioned therapeutic materials for optimal spatial and 
temporal control over drug release. The main goal of this review is to be used as a source 
of relevant literature for othersinterested in the field of camptothecin-based 
therapeutics.To this end, final remarks on the most important formulations currently 
under clinical trial are provided. 
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Camptothecin (CPT) is a water insoluble, natural pentacyclic alkaloid isolated from the 
oriental tree Camptotheca accuminata by Wall et al. in 1966 [1]. CPT is well-known for 
its antitumor activity against a wide spectrum of human cancers [2-8]. In addition, a 
variety of biological activities, such as pesticidal [9-10], antipsoriasis [11-12], antiparasitic 
[13], antifungal [14], antimicrobial [15] and antiviral [16-17] has been described for this 
compound. Certainly, several researchers have reported that CPT inhibits a cellular 
enzyme DNA topoisomerase I and induces apoptosis in various cancer cells. [18-19] 
CPT is a planar pentacyclic quinoline that includes 3 rings of pyrrolo- (3,4-β)- quinoline 
part (A, B, and C rings), an unsaturated pyridone moiety in ring D and a α-hydroxy lactone 
ring (E ring), containing one chiral center with (S)-configuration (Fig. 1) [20-21]. It is worth 
noting that the isomer 20(R) hydroxyl has little activity while the isomer 20(S) is between 
10 and 100 fold more active [22]. Also, it is known that E-ring exists in equilibrium 
between the lactone form (closed ring, not water insoluble) and the carboxylate form 
(open ring, water soluble). In acidic pH the lactone predominates which, according to 






































However, at physiological pH, the lactone ring is converted into the carboxylate, much 
less active, which predominates at neutral and alkaline pH [23-24]. 
Unfortunately, CPT presents some major limitations with regards to therapeutic 
application, like poor water solubility and the rapid lactone ring hydrolysis at physiological 
pH, which gives rise to the inactive carboxylate form [25]. In addition, CPT is extremely 
insoluble in organic compounds except for dimethyl sulfoxide, in which it shows moderate 
solubility [26]. Due to CPT insolubility in biocompatible solvents, it is very difficult to apply 
conventional drug administration routes, including oral, intravenous or intramuscular 
injection, to distribute this compound throughout the body [27]. Furthermore, there are 
other negatives aspects that limit the use of CPT in clinical trials: pronounced loss of 
activity due to lactone-ring hydrolysis, reversibility of drug-target interaction and severe 
toxicity, including hemorrhagic cystitis and myelotoxicity [28]. All these drawbacks have 
precluded its clinical application, making necessary to develop alternative compounds 
and structures for CPT use in humans.  
In an effort to improve CPT solubility and pharmacokinetics structural derivatives as 
topotecan and irinotecan have been developed [29-30] (see Table 1). Unfortunately, as 
it will be reported later on, CPT quinoline structure modification usually brings out a 
dramatic drop of cytotoxic activity, which results one order or even lower than pristine 
drug, strongly limiting the therapeutic use. 
To overcome these issues two strategies have been pointed out for safety and efficient 
CPT delivery to target cells: i) structural analogues, in which the CPT molecule is 
chemically modified for increased solubility and stability in biological fluids; and ii) 
nanomedicines, wherein CPT is incorporated by physico-chemical methods to 
nanoparticles which act as stable carriers for drug delivery. In this review, we summarize 
the most advanced and recent achievements in the design, synthesis and development 
of CPT analogues and nanomedicines, including the most relevant formulations currently 
under clinical use.  
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2. Campthotecin analogues 
Since the discovery of CPT and the associated therapeutic limitations, huge scientific 
efforts are being made to improve the pharmacokinetics, drug resistance, clinical 
efficacy, and toxicity profiles of the original molecule, by introducing organic ligands [31-
36].  
 
2.1. Structure-activity relationship  
In literature, numerous structure-activity relationship (SAR) studies have focused in 
different modifications of A, B, C, D and E rings of CPT to obtain more active analogs 
(Table 1 and Fig. 2). It was reported that the  complete pentacyclic ring structure was 
essential for its activity and the planar structure of this system was suggested to be one 
of the most influential structural element. In addition, the hydroxylactone ring is the most 
critical region for the activity [35,37-38].  
Most derivatives of CPT have been obtained through modifications of the quinolone A-B 
ring. However, to date, only two of these CPT analogues have been approved for clinical 
use. Modifications may include substitution at 7, 9, 10 or 11 positions [2, 39-43]. In 
general, substitution at C12 is unfavorable to biological activity. This loss in the activity 
can be due to steric and electronic disturbances at the quinoline nitrogen, which might 
interfere interaction with DNA [44]. Monosubstitution at C9, C10 or C11 by amine or 
hydroxyl group make it possible to obtain compounds with more antitumoral activity, 
whereas substitution of positions 9 and 10 by halides or other electron-rich groups and 
substitution of position 11 with fluorine or cyano groups increase the DNA topo I inhibition 
ability [44-45]. Moreover, modifications at C10 and C11 positions are adverse for 
antitumor activity with the exception of the 10,11-methyl or ethylenedioxy, substitutions 
favorable to DNA topo I inhibition [46-47]. Conversely, other ring combinations in 
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positions 7 and 9 do not positively affect DNA topo I activity, whereas substitutions at C7 
and C10 showed powerful cytotoxicity [48-49].  
Table 1. CPT analogues. Most important structural modifications in A, B, C, D, E rings. 
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H H H N
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__ 0.008 0.3-0.5d Phase III [34,70] 
Lurtotecan 
(GG-211) 
__ O O  H 
N NCH3
 0.006 1.2 Phase II [34,71] 
CPTc H H H H 0.046  - [36] 
a IC50: drug concentration needed to inhibit 50% of the cell growth compared to growth of the untreated 
control cells. All compounds were tested in a variety of human tumor cell lines. 
bMTD: Maximun tolerated dose 
c Solubility in water at 25 ºC: Irinotecan (HCl)=25 mM; Topotecan (HCl)=100 mM; CPT= 2.9 mM. 












Fig. 2. Scheme of different CPT structural modifications. Where possible, the structure 



















































































































Also, a series of 7-substituted CPTs were developed to overcome the instability of 
lactone ring. All of them showed significantly improved cytotoxic/antitumor potency and 
stability [50]. On the other hand, few studies have focused on modifications of C and D 
rings. In general, modifications in position 5, 14 and 17 of these rings reduce cytotoxicity 
as CPT loses its planarity. Substitution of alkoxy or several other groups at position 5 are 
reasonably well tolerated when the substituents at position 9 are nitro or hydroxyl groups 
[51]. Besides, reduction of carbonyl at C17 leads to inactive compounds [34-35,52-54]. 
At this point, it must be emphasized that E ring and stereochemistry at 20 position are 
crucial for CPT activity. One of the major drawbacks observed in ring E modification is 
that, due to the presence of α-OH group, under physiological conditions the lactone ring 
is cleavaged to inactive carboxylate form. Here, with the aim of increasing lactone ring 
stability, several derivatives have been reported but with lower cytotoxicity. Also, it is 
noteworthy that α-hydroxylactone replacement by β-hydroxylactone improves lactone 
cytotoxicity and stability [35,38].  
More recent studies have been focused on different conjugates (ester, amide, carbonate, 
etc.) at C20 position aimed at new CPT structures. As it will be detailed later on (section 
3.1), CPT can be covalently linked by 20-hydroxyl group to numerous organic moieties, 
including glycerides, poly(amidoamine) and triazine derivatives, polyethylene glycol, 
poly(N-(2-hydroxypropyl) methacrylamide), polyvinylpyrrolidone, polyethyleneimine, 
poly(L-glutamic acid), β-cyclodextrins, hyaluronic acid, chitosan and polypeptides. 
Actually, these systems improve CPT delivery and bioavailability, and may also introduce 
alternative administration routes to parenteral injection [32,55-58]. 
 
2.2. Camptothecin structural derivatives at the clinical stage 
Although a variety of CPT derivatives have been developed, only a short list has been 
investigated in clinical trials [59]. Herein, we try to mention the most representative CPT-
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based molecules at the clinical stage. Such illustrative examples are presented in Table 
1.  
In particular, CPT-11 (also known as irinotecan) was approved by the Food and Drug 
Administration (FDA) and is used to treat colorectal and other cancers. In vivo, CPT-11 
is converted into the active metabolite SN38 by the hepatic carboxylesterase enzyme. 
This metabolite allows to overcome the problems of irinotecan, including intestinal 
toxicity and neutropenia [60]. Furthermore, SN-38 is one of the most active analogues 
and shows higher cytotoxic activity than irinotecan [61-62]. However, the principle issue 
of SN38 is its poor water solubility [63].  
Topotecan was the first topoisomerase I inhibitor approved by the FDA and is used to 
treat ovarian and lung cancers. This compound has shown activity against a broad 
spectrum of cancers cell lines. A report about Phase II testing [64], mentions that the 
efficacy of topotecan as second treatment in ovarian cancer was demonstrated among 
92 patients. Although this compound was tolerated but different side effects such as 
alopecia, nausea and vomiting appeared.  
Another CPT derivative is rubitecan (9-nitrocamptothecin, 9-NC), a water insoluble 
analogue currently in Phase III trial. This compound can be metabolically converted in 
vivo to 9-aminocamptothecin (9-AC), which showed anticancer activity in Swiss 
immunodeficient (nude) mice of the NIH-1 high fertility strain inoculated with different 
breast carcinoma cell lines (MDA-MD-134 and MDA-MB-231), at a concentration 
several-fold lower than CPT [65]. Also, rubitecan, showed similar activity than CPT 
against a broad spectrum of tumor types in human tumor xenograft models [66], and in 
a Phase II trial over 58 advanced pancreatic carcinoma patients, it achieved >50% tumor 
shrinkage in 7 cases (16%), being well tolerated by most of patients (only 3 patients 
discontinued treatment due to toxicity) [67]. 
Conversely, belotecan (CKD-602) is another derivative of CPT in Phase II that solves 
the problem of water solubility. This compound showed more activity than topotecan 
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against a broad spectrum of cancers cell lines and acceptable toxicity [68]. Recently, 
different clinical studies of belotecan in combination with other chemotherapy drugs such 
as cisplatin have been investigated [69]. This pharmacological combination 
demonstrated a promising efficacy in patients with advanced stage small cell lung 
cancer, although the hematologic toxicity of this regimen requires substantial attention. 
Exatecan (DX-8951f) is an intrinsically active compound also in Phase II. This CPT 
analogue showed higher efficacy against human tumor xenografts (colon, lung, breast, 
renal) than topotecan and irinotecan. [70]. In an experiment that included over 31 
patients with different solid malignancies, the administration of exatecan as a protracted 
21-day continuous i.v. infusion showed limited systemic toxicity (with a significant 
reduction of myelosuppresive effects, neutropenia and thrombocytopenia) and efficient 
anticancer activity.  
Finally, lurtotecan (GG-211) is also a water soluble CPT analogue currently in Phase II. 
This compound showed significant cytotoxicity against HT-29 and SW-48 human colon 
cancer cells, PC-3 human prostate cancer cell line, MX-1 human breast cancer cells, 
H460 human lung cancer cell line, SKOV3 human ovarian cancer cells and KB human 
epidermoid carcinoma cell line [71].  
 
3. Nanoparticles as drug delivery systems for camptothecin 
Many types of nanovehicles have been developed for CPT delivery, and these drug 
delivery systems (DDSs) may be classified in several ways, according to their chemical 
nature, structure, composition, morphology, etc. Herein, we present a systematic 
classification of CPT nanocarriers according to their chemical nature in organic, inorganic 
and hybrid materials, presenting different properties and behaviors [72-75]. These novel 
nanoplatforms have been designed to solve most of the antitumor drug limitations, 
improving CPT pharmacokinetics, which is affected by poor water solubility, rapid plasma 
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clearance, high systemic toxicity and poor selectivity towards cancer cells [36]. A variety 
of DDSs have been developed and allow CPT incorporation. In addition, these DDSs 
can conjugate the drug in different ways, as adsorption, encapsulation or covalent 
bonding [76], working as inert supports to transport the drug to tumor [77]. In this sense, 
some major advantages of these DDSs over free CPT are: improved solubility, lactone 
ring stability, half-life extension, biocompatibility and control drug release rates, which 
allow significant advances at the clinical stage [78-79].  
 
3.1. Organic nanocarriers 
The use of organic pharmaceutical nanocarriers to enhance the in vivo efficacy of many 
drugs has been well established in the last two decades [80]. To prepare such smart 
systems, therapeutic moieties must be simultaneously encapsulated or assembled on 
the surface [81]. Organic carriers are carbon-based (with the exception of carbon 
nanotubes that are considered inorganic) and are generally characterized by their high 
biocompatibility, good solubility or colloidal stability in physiological fluids and quick 
biodegradability, resulting in excellent pharmacokinetic profiles of the delivered drugs. 
However, their usual limitations include restricted functionalization (with hinders not only 
drug loading, but also the incorporation of targeting molecules and cromophores), low 
stability (especially under enzymatic activity), and the lack of specific physicochemical 
properties, as optical activity or magnetism, which are useful in diagnostics [82]. In these 
materials, drugs are often trapped or bound within the matrix.  
 Although different classifications may be used, we have organized the various organic 
nanocontainers according to their chemical nature, resulting in five key groups: micelles, 






Polymeric micelles are expected to increase the accumulation of drugs in tumor tissues 
by taking advantage of the enhanced permeability retention (EPR) effect [83]. Actually, 
micelle systems can also incorporate various kinds of drugs into their inner core with 
relatively high stability by chemical conjugation or physical entrapment [84-85]. Also, the 
size of micelles can be controlled within the diameter range of 20-100 nm. Therefore, it 
is expected that the incidence of drug-induced side effects may be decreased due to 
reduced drug distribution in normal tissues [86]. 
At this point, polymeric micelles composed of various poly(ethylene glycol)-
poly(aspartate ester) block copolymers have been physically loaded with CPT, to 
improve drug aqueous solubility and stability in biological fluids [87-89]. Here, it was 
observed that the stability of CPT-loaded micelles depended on the amount of benzyl 
esters and poly(ethylene glycol) (PEG) length in the polymers. After intravenous 
administration of CPT-loaded micelles to male ddY mice via lateral veins, it was 
concluded that sample using PEG 5000, 27 aspartic acid (Asp) units and 57-75% benzyl 
esterification of Asp residue was the most stable formulation, showing an extended 
circulation period in blood stream [82]. However, it is not clear if CPT is safely packaged 
in these micelles, which is crucial to avoid premature release before reaching tumor cells.  
Another nanomicelle system was developed by using α,β-poly[(N-carboxybutil)-L-
aspartamide] (PBAsp) with different CPT loading (PBAsp-CPT), through esterification 
between PBAsp carboxyl groups and CPT 20-hydroxyl [90-91] (Fig. 3). Subsequently, 
spherical nanomicelles were produced in aqueous medium. In this case, CPT was 
sequestered toward the core whereas PBAsp backbone formed the hydrophilic shell. 
Unfortunately, PBAsp-CPT solubility decreased quickly as the amount of CPT increased. 
Anyway, in vitro cytotoxicity assays of PBAsp-CPT (2,1% CPT) against L929 mouse 
muscular cell line showed less toxicity than free CPT (5-10% activity drop depending of 








Fig. 3. Schematic illustration of the conjugate made of α,β-poly[(N-carboxybutil)-L-
aspartamide] and CPT. (Reprinted from ref. 90, Copyright © 2010, with permission from 
Elsevier) 
 
In addition, CPT was also encapsulated in different quantities in 45 nm diameter micelles 
of poly(ethylene glycol)-poly(L-lysine) block copolymer and 3-3’-dithiodipropionic acid. 
Then, it was studied CPT release in response to cytosol reductive conditions was studied 
by exploiting the permeabilization of endosomes upon light irradiation (using a halogen 
lamp with a 400-700 nm band-pass filter) induced by photosensitizer agents, such as 
Photofrin. Experiments in BALB/c nu/nu mice inoculated subcutaneously with AY27 
urothelial cancer cells confirmed that after endosomal permeabilization CPT loaded 
micelles escaped (from endocytic vesicles) into the cytosol, promoting drug release of 
more than 70% from micelles in the irradiated tissue (fluence rate to induce the 
photochemical internalization effect, 100 mW/cm2; time, 1000 s) and better antitumor 
activity than the free drug [92]. 
 
3.1.2. Liposomes 
Liposomes are a well-studied biocompatible carrier playing a key role in nanotechnology-
based drug delivery [93]. Liposomes protect the encapsulated drugs form structural 
transformation or chemical degradation by isolating them from the surrounding 
environment. However, formulating CPT liposomes is challenging due to different 






















acceptable solvents, as well as it associates with simple phospholipid bilayers. Actually, 
the outcome in most of these approaches is hampered by incomplete separation of free 
and liposomal CPT, which affects to biological activity and biodistribution. In that sense, 
a study over several CPT liposome formulations of different nature (cationic, anionic and 
neutral phospholipids) prepared by drug encapsulation, reported cationic compositions 
as the best option to increase CPT water solubility [94]. 
In one of the first attempts to deliver CPT within liposomes, the lipid-complexed 
formulation (particle size range 20-200 nm) showed significant advantages with regards 
to the naked drug for intravenous administration in clinically relevant lipid-drug ratios 
(12.5:1 w/w) [95]. CPT-loaded liposomes (LC-CPT) had an in vitro antitumor activity 
similar to that of free CPT and displayed similar cytotoxicity against multidrug resistance 
(MDR-1) negative human cervix carcinoma KB-V1 cells and MDR-1 positive human 
cervix carcinoma KB-3-1 cell line. However, the biodistribution of CPT in ICR Swiss mice 
was severely affected by lipid complexation, as CPT achieved the greatest concentration 
in pulmonary parenchyma, while liposomes accumulated mostly at gastrointestinal tract, 
probably due to the rapid processing of LC-CPT in liver and elimination via the gut. 
Furthermore, LC-CPT showed higher antitumor activity than free CPT in in vivo testing 
over B6D2F1 mice bearing intraperitoneal tumors of L1210 mouse lymphocytic leukemia 
cells or P388 mouse leukemia cell line. 
CPT-loaded liposomes with average particle size of about 150 nm were synthesized by 
a lipid-film hydration method [96]. In a first step, liposomes were formulated by addition 
of an artificial lipid with a phenyl group (3,5-bis(dodecyloxy)benzoic acid) to polyethylene 
glycol-modified liposomes and, subsequently, liposome surface was coated with human 
serum albumin. Here, CPT was entrapped with about 80% efficiency due to the 
interaction with phenyl group-containing lipids. After intravenous injection, these 
protected liposomes  showed much higher therapeutic activity than CPT in CDF1 female 
mice bearing mouse colon adenocarcinoma 26 tumors (tumor volume in CPT-treated 
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specimens increased up to 5-fold that of liposome-treated mice), with high accumulation 
in malign tissue (9.6-fold more efficiently than CPT solution). 
3.1.3 Dendrimers 
Dendrimers have received much attention in drug delivery, as they are highly branched, 
multivalent and tunable polymers for different architecture, size, shape and surface 
properties [97]. Dendrimers are usually classified by generation (denominated G), which 
refers to the number of repeated branching cycles that are performed during its 
synthesis. Due to their positive charge, cationic dendrimers as poly(amidoamine) 
(PAMAM) and triazine derivatives conjugate easily with the phenolic 20-hydroxyl group 
of CPT, resulting in stable nanomedicines. At this point, it has been proved that CPT 
solubility increases with PAMAM generation [98]. Here, PAMAM dendrimers of four (G4), 
five (G5) and six (G6) generation were prepared and their solubility in aqueous medium 
and the interaction with CPT (carboxylate form or lactone form) were evaluated. The 
study showed that G6 PAMAN enhanced CPT water solubility in comparison with G4 
PAMAN. This can be partly explained by the fact that the number of primary and tertiary 
amines in G6 dendrimer increases and could entrap more hydrophobic molecules inside. 
However, the cationic nature of dendrimers represents a serious toxicity issue, as it 
promotes a strong reaction with serum proteins, hemolysis and hepatic toxicity. 
Furthermore, their chronic toxicity is still to be determined [99].  
A relevant PAMAM second generation (G2) model was synthesized with four molecules 
of CPT per unit and a trigger that allows activation with penicillin-G-amidase (PGA). In 
this system, the cleavage of the phenylacetamide group by PGA triggered the 
disassembly of dendron through a known self-immolative reaction sequence (Fig. 4) 
[100]. This conjugate demonstrated outstanding improvement of CPT cytotoxic activity, 
as cell-growth inhibition assays indicated that half maximal inhibitory concentration (IC50) 
value for the dendrimer was between 100- and 1000-fold lower than free CPT against 
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MOLT-3 lymphoblastic leukemia, JURKAT human leukemia T and HEK-293 human 









Fig. 4. Molecular structure of second-generation PAMAM with a trigger designed for 
activation by penicillin-G-amidase. The figure shows CPT in blue, penicillin-G-amidase 
in red, dendritic structure in black and poly(ethylene glycol)-azide units in purple. 
(Reprinted with permission from ref. 100. Copyright © 2006 American Chemical Society) 
 
In one important contribution, triazine dendrimer CPT derivatives were synthesized and 
their cytotoxic activity evaluated against MCF-7 human breast carcinoma cells and HT-
29 colon carcinoma cell lines [101]. For this sake, CPT was conjugated with isonipecotic 
acid through an ester bond, and the obtained secondary amine was highly reactive and 
combined with the triazine, allowing to obtain the desired dendrimers, which showed 
almost similar cytotoxicity to free CPT. 
Click chemistry has been widely used to improve coupling reaction efficacy in the 
synthesis of CPT-dendrimer conjugates [102-103]. In a relevant study, CPT was 
esterified with a spacer 1-azido-3,6,9,12,15-pentaoxaoctadecan-18-oic acid (APO). On 
the other hand, propargylamine (PPA) and methoxypoly(ethylene glycol) amine were 

















































































dendrimer (G4.5-PPA) via click chemistry. Nearly 100% of the CPT molecules were 
covalently conjugated to the dendrimer and the drug was released by ester bond 
hydrolysis. This new dendrimer-CPT was more cytotoxic than free CPT (IC50 value 
increase of 185-fold in U1242 human glioma cells).  
3.1.4. Organic polymers and biopolymers   
In the last years, a myriad of polymer therapeutics, including polymeric drugs, polymer-
protein conjugates, polyplexes, polymeric micelles and polymer-drug conjugates [104-
105], have received special attention as drug delivery systems and have been 
established as first-generation nanomedicines. Most of these polymers present 
advantages such as absence of toxicity, biocompatibility, biodegradability and small 
particle size, allowing them to circulate in the bloodstream for long periods of time [106-
107]. Conversely, the main issues of these materials are their fast biological degradation, 
which may cause leaching of CPT important quantities of CPT into the blood stream and 
interstitial fluids, and their variable loading capability due to limited functionalization. 
Nanoparticles of synthetic polymers, including polyethylene glycol, poly(N-(2-
hydroxypropyl) methacrylamide), polyvinylpyrrolidone, polyethyleneimine, poly(L-
glutamic acid) and β-cyclodextrins, and natural polymers such as hyaluronic acid, 
chitosan and polypeptides, are the most commonly reported for CPT delivery [108-109]. 
In addition, the presence of a covalent chemical bond between a water-soluble polymeric 
carrier and the bioactive molecule confers enhanced solubility and stability, allowing to 
improve the pharmacokinetic profile of the bioactive molecule [36, 110-112]. 
CPT can be encapsulated in hydrophobic polymers or amphiphilic copolymers for safety 
delivery. At this point, one interesting approach that allows exceptionally high drug 
loading is to polymerize the drug itself. In one representative example, a dimeric CPT 
derivative, CPT-SS-CPT, bearing a trigger responsive domain was used as the core-
constructing unit of the nanoparticle [113]. Here, CPT molecules are stably conjugated 
via carbonate linkages that are subject to triggered bond cleavage and subsequent drug 
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release by a reducing reagent (Fig. 5). Upon triggering, cleavage of the disulfide bond in 
CPT-SS-CPT would result in decomposition of the drug dimer, releasing CPT in its 
authentic form. Unfortunately, CPT-SS-CPT has much lower water solubility (less than 
10 ng/mL) than CPT (3 μg/mL), presumably due to stronger intermolecular interactions 
between molecules. However, when CPT-SS-CPT was encapsulated in methoxy 
poly(ethylene glycol)-poly(lactide) (mPEG-PLA, Mw 3500-5000) empty micelles, drug-
loaded nanoparticles stable in phosphate buffer saline (PBS) and human serum for at 
least 3 days were formed, with particle diameter of about 180 nm. The anticancer effect 
of these CPT-SS-CPT/mPEG-PLA nanoparticles was then evaluated in vitro by MTT 
assay over HeLa human cervix carcinoma cell line. The IC50 of CPT-SS-CPT/mPEG-
PLA was 114 nM, compared to 17 nM for free CPT, but the main advantages of this 
nanoconjugate are the lack of systemic toxicity, as CPT release only takes place through 











Fig. 5. Chemical structure of dimeric CPT derivative, CPT-SS-CPT and release 
mechanism of thiol-triggered drug release. (Reprinted partially with permission from ref. 


























































































One of the best performances to improve CPT stability and solubility in biological 
conditions has been to covalently conjugate it with a β-cyclodextrin (β-CD) derivative 
condensed with difunctionalized PEG comonomers, obtaining linear high molecular 
weight (over 50 kDa) β-cyclodextrin-CPT based polymers [114-117]. For this purpose, a 
CPT-glycine ester derivative was prepared, which was subsequently linked to the β-CD 
derivative by amide bond (Fig. 6). This way, the solubility of CPT is increased by more 
than three orders of magnitude [114]. Moreover, this nanomedicine showed higher 
concentration in tumor and superior efficacy than irinotecan in the treatment of CD-1 
female athymic nude mice bearing LS174T human colon carcinoma, HT-29 human 
colorectal carcinoma, H1299 human non-small-cell lung cancer model or Panc-1 human 
pancreatic cancer cell tumors [115-116,118-119]. As a consequence, a commercial 









Fig. 6. Schematic illustration of the synthesis steps involved in preparing 6A,6D-Diiodo-
6A,6D-dideoxy-cyclodextrin (CDDI) polymerized derivative. (Reprinted with permission 
from ref. 114. Copyright © 2003 American Chemical Society) 
 
β-cyclodextrine has also been the aim of further development to improve CPT solubility 
and stability. In a relevant study, hollow nanospheres were prepared based on β-
cyclodextrin-grafted α, β-poly(aspartic acid) (β-CD-graft-PAsp). This conjugate favored 
the inclusion of CPT and lactone ring stability. In vitro cytotoxicity assays in L929 mouse 
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muscular cell line suggested a decrease of cytotoxicity at higher dose of CPT@β-CD-
graft-PAsp [120]. 
A different CPT delivery system based in β-cyclodextrine is the nanosponge (CDN) 
prepared to improve CPT transport to prostate cancer cells, including androgen-
refractory (DU-145 and PC3 human prostate cancer cell lines) and sensitive (LnCaP 
human prostate cancer cells) cell lines. CPT was incorporated in the CDN structure and 
its interaction with the nanosponge was confirmed by thermal analysis. Cell proliferation 
and clonogenic assays showed a greater responsiveness of CDN-CPT against PC3 and 
DU145 cell lines, blocking colony formation and cell growth starting at 1 nM dose. 
Besides, in vitro assays against LNCaP cell line, demonstrated that CDN-CPT inhibited 
androgen receptor gene expression in androgen-resistance prostate cancer patients at 
10 nM, whilst CPT was inactive at similar doses [121]. 
Poly(L-glutamic acid) (PGA) polymers have been combined with CPT by direct 
esterification [122], or by using a short linker, like glycine [123], obtaining loadings of 
nearly 40%. The administration of four doses of 7% CPT-loaded PGA by iv injection (one 
single dose every four days, with an equivalent CPT dose of 40 mg/kg) over Sprague-
Dawley female athymic nude mice bearing NCI-H322 human lung carcinoma tumors 
showed a 32-day tumor growth delay with regards to untreated mice, prolonging the 
median survival of treated mice by 4-fold [122]. Moreover, by increasing polymer 
molecular weight up to 50 kDa and CPT loading up to 37%, it was reported a tumor 
growth was delayed to less than half in comparison to untreated mice after a 30 mg/kg 
CPT equivalent dose over athymic NCr (nu/nu) mice bearing NCI-H460 human lung large 
cell carcinoma tumors [123]. 
In the last decade, among different biopolymers, the use of chitosan for drug delivery 
has been widespread in order to improve biocompatibility and bioavailability of cytotoxic 
compounds [124]. In one of those applications to prepare a CPT delivery carrier, 
hydrophobically modified glycol chitosan (HGC) nanoparticles were constructed by 
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chemical conjugation of hydrophobic 5b-cholanic acid moieties to the hydrophilic glycol 
chitosan backbone [125]. CPT was easily encapsulated into HGC nanoparticles (CPT-
HGC, 280-330 nm in diameter), which showed sustained release for one week. CPT-
HGC exhibited significant antitumor effects and high tumor targeting ability towards 
MDA-MB231 human breast cancer xenografts subcutaneously implanted in nude mice. 
Tumor growth was significantly inhibited after iv injection of CPT-HGC nanoparticles at 
doses of 10 mg/kg and 30 mg/kg, compared to free CPT at a dose of 30 mg/kg. 
More recently, CPT has been conjugated with hyaluronic acid (HA-CPT) with variable 
molecular weight, in order to overcome the low solubility and poor targeting ability of the 
naked drug [32]. Here, CPT was incorporated using two linkage molecules such as 
succinate and adipic acid dihydrazide. The authors studied the influence of the polymer 
molecular weight over solubility, drug loading and stability. Solubility assays confirmed 
that these conjugates increase CPT solubility, mostly those samples with lower 
molecular weight. Furthermore, in vitro efficacy assays demonstrated that the antitumor 
activity of HA-CPT polymers were higher than the naked drug against HepG2 human 
liver cancer cell line due to an HA receptor overexpression.   
A singular and very efficient approach for CPT delivery has been achieved by 
encapsulating the drug during self-assembling peptide amphiphile (PA) nanofibers 
through a solvent evaporation technique [126]. In vitro efficacy assays against BT-474 
human breast cancer cells, MCF-7 human breast adenocarcinoma cell line and SKBR-3 
human breast cancer cell line, demonstrated that the intracellular release of the cargo 
induced cell death with half maximal inhibitory concentration (IC50) values similar to those 
observed with the naked drug. Furthermore, in vivo assays of the PA-encapsulated CPT 
in a mouse orthotopic xenograft model (Sprague-Dawley female athymic nude mice) of 
BT-474 human breast carcinoma suggested that the nanomaterial delayed 




3.2. Inorganic nanocarriers 
Currently, a wide variety of inorganic nanoparticles may have biological applications. 
They usually show high stability in the biological environment, ease of functionalization 
(allowing multifunctionality) and unique physico-chemical properties (optical, magnetic 
and electronic) that can be tailored by controlling particle structure, composition, size 
and shape. Materials as semiconductor quantum dots, magnetic nanoparticles and 
plasmonic nanoparticles, among others, have been proposed for imaging and therapy 
[127,128]. However, despite the interest raised by inorganic nanoparticles as DDSs, 
most of these systems suffer of biocompatibility issues, mostly related to the toxicity of 
some structural components and the strong interaction with serum proteins, which results 
in rapid blood clearance and hepatic removal [129]. Moreover, occasionally, the 
elimination from organic tissues may be an issue, involving the accumulation in the body 
of highly toxic elements. Herein, we present a few cases of simple inorganic 
nanoparticles that have found application for delivery of CPT, metal oxides and carbon 
nanotubes.  
3.2.1. Metal oxide nanoparticles 
The most significant use of transition metal oxides for biological purposes are magnetic 
processes, such as magnetic resonance imaging (MRI) and magnetic induction 
hyperthermia. Typically, paramagnetic oxide nanoparticles show a critical size of around 
10-20 nm, which is dependent on the material, have a large magnetic moment and are 
stable in physiological fluids [129]. 
Iron oxide (Fe3O4) hollow monodispersed spheres of about 200 nm mean diameter, and 
composed of small primary nanoparticles with a 30-40 nm average size, were 
synthesized using a one-pot solvothermal method, and further loaded with CPT by 
incubation in a chloroform solution [130]. These nanospheres showed negligible drug 
leakage before cell internalization, and exhibited slightly higher cytotoxicity than free CPT 
against 786-O, HepG2 and HeLa cell lines, due to the enhanced solubility of the 
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transported drug. Furthermore, non-loaded Fe3O4 hollow spheres showed nearly no 
cytotoxicity towards the cells, although there is no report on the stability of these 
nanocarriers in in vivo conditions.  
Very high CPT loading has been achieved into iron oxide (Fe3O4) superparamagnetic 
nanoparticles (SPIONs) with 14 nm average size obtained through an iron co-
precipitation method under alkaline conditions [131]. Formulations containing 13 wt% 
CPT were produced by incorporation of the drug to a SPION aqueous solution; this 
increased up to 26 wt% CPT by functionalizing SPION surface with a PEG. The high 
loading capacity was attributed to the amphiphilic nature of the PEG molecule. 
Nevertheless, this did not bring about any improvements in cytotoxic activity, as CPT-
loaded nanocarriers demonstrated about 10-15% lower apoptotic levels over H460 cell 
culture than the free drug. This was justified on the basis of CPT slow release profile 
from the SPION formulations.  
3.1.2. Carbon nanotubes 
Carbon nanotubes (CNTs) have recently emerged as a new alternative vehicle for 
transporting and releasing therapeutic molecules, due to their high surface areas 
[127,132]. However, several concerns relating to pharmacokinetics, biodistribution and 
toxicity (mostly by liver and kidney accumulation), must be solved before they can go 
into clinical application. In this sense, surface chemical modification becomes a crucial 
step for preparation of soluble CNTs and efficient drug incorporation [127].  
In an attempt to raise CPT water solubility and antitumor efficacy, non-covalent 
supramolecular attachment on multiwall carbon nanotubes (MWCNTs) has been carried 
out. Surface oxidation of MWCNTs followed by functionalization with poly(vinyl) alcohol 
(PVA) allowed CPT loading via π-π interactions (Fig. 7) [133]. This construct was found 
to be very stable in simulated body fluid and, in in vitro testing, it was approximately 15-
fold more cytotoxic than free CPT against MDA-MB231 human breast cancer and 












Fig. 7. (A) Schematic depiction of CPT loaded MWCNT-PVA. The figure shows CPT 
molecule in red, MWCNT structure in black and polymer PVA in blue. (B) UV spectra of 
multiwall CNT-PVA and CNT-PVA-CPT samples with different concentrations. 
(Reprinted from ref. 133 with permission of The Royal Society of Chemistry) 
 
Another singular CNT-based material suitable for CPT delivery are glyconanosomes 
(GNS). These are water-soluble nanodisks created by supramolecular self-organization 
and photopolymerization of diacetylenic-based glycolipids on single wall carbon 
nanotubes (SWCNTs) surface, and subsequently used as molecular scaffolds that 
determine their shape and topology (Fig. 8) [134]. Experiments against MCF-7 human 
breast cancer cells suggested that CPT-loaded GNS-SWCNTs presented higher 
antitumor activity than the naked drug (killed more than 65% of MCF-7 human breast 
cancer cells while CPT alone affected less than 55% MCF-7 cells), which could be 
explained because the interaction of GNS/CPT could interfere with cellular CPT 
detoxification mechanism in such a way that intracellular CPT retention time increases, 


















Fig. 8. (A) Schematic representations of the self-organization and synthesis of 
glyconanosomes (GNS). The inset is a TEM micrograph of SWCNT nanoassemblies and 
their idealized representative figures. (B) Schematic representation of the ultrasonication 
setup for obtaining GNS. (C) Structural and chemical composition of a GNS. (Reprinted 
with permission from ref. 134. Copyright © 2013 American Chemical Society) 
 
3.3. Hybrid nanocarriers 
As commented before, fully inorganic systems found strong limitations for biological use, 
due to possible compositional toxicity and severe interaction with serum proteins. For 
this reason, inorganic nanocarriers are better handled surface modified or combined with 
organic components, which provide good stability in physiological fluids, low toxicity and 
immunogenicity, and minimized reactions with serum proteins, to control their fate in 
































































distributed in the nanoscale or molecular range are hybrid materials. Typically, the hybrid 
nanocontainers are made of inorganic and organic building blocks, presenting unique 
properties depending on the spatial and size distribution of their components [135-136]. 
Actually, efforts have been done to design hybrid devices combining different functions 
or strengths of the individual components in a synergic way, or even to compensate for 
the weaknesses of one another [137]. Whilst organic component provides good 
biocompatibility and better solubility in physiological fluids, the inorganic moiety offers 
almost unlimited external surface area to bind different functionalities, improving the 
capabilities of the DDS. On the other hand, the main handicap of these systems is the 
lack of long-term toxicity studies about the possible interactions within the body of the 
different components.  
A myriad of compositions and models have been reported with potential use in 
nanomedicine. According to their structural configuration, we have distinguished three 
different types of hybrid materials with applications as DDS: organic-inorganic 
nanoparticles, core-shell systems and metal-organic frameworks. However, in this 
section we only present a brief description of some of the most representative examples 
of the different systems proposed, as most of these hybrid nanocarriers for CPT delivery 
carry molecular devices sensitive to specific physico-chemical stimuli, which act as 
triggers for selective release activation at the targeting tissues and cells. These last are 
described in detail in the next section.  
3.2.1. Organic-inorganic nanoparticles 
Organic-inorganic hybrid materials combining the individual advantages of both 
components while overcoming their intrinsic drawbacks have received extraordinary 
attention in the last decade. In the case of biomedical applications, their complex 
chemical composition, their variable structure, but mostly the inherent multifunctional 
property, offer plenty of room for the development of novel systems that are able to carry 
out associate actions inside the body, as imaging and therapeutics. 
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Mesoporous silica nanoparticles (MSNs) modified with organic ligands are probably the 
most widely used inorganic material for hybrid DDS development [138]. These particles 
have large surface areas and porous interiors that can be used as reservoirs for storing 
hydrophobic drugs as CPT. Moreover, particle surface and pore size can be easily 
tailored to selectively store and deliver different molecules. In this context, MSNs were 
stabilized in aqueous medium by surface modification with methylphophonate groups, 
which reduced aggregation [139]. Then CPT was absorbed within the 2 nm diameter 
pores and the particles were incubated with different cells lines (PANC-1 human 
pancreatic carcinoma cell line, Capan-1 human pancreatic ductal adenocarcinoma cell 
line, AsPc-1 human pancreatic adenocarcinoma cells, SW 480 human colon 
adenocarcinoma cell line and MKN 45 human gastric cancer cell line) to determine if they 
were able to transport the hydrophobic drug into the cancer cell. In all cases, results 
indicated that the cytotoxic efficacy of CPT-loaded MSNs was very similar to that of the 
dissolved CPT. In an ulterior study, folic acid was incorporated to the surface of MSNs 
(FA-MSNs) as targeting molecule to pancreatic cancer cells. Then, in vivo biodistribution, 
therapeutic efficacy and biocompatibility of the CPT-loaded FA-MSN were evaluated in 
BALB/cAnNCrj-nu nude mice bearing MCF-7 human breast carcinoma tumors. These 
authors showed that nanoparticles were able to repress subcutaneous tumor growth with 
a minimum therapeutic dose of about 0.5 mg/kg CPT-loaded FA-MSN for complete tumor 
growth inhibition. Inhibition of tumor growth was also complete in the CPT-treated group 
but with clear signs of toxicity in blood analysis, as high concentration of liver enzymes, 
hypoalbuminemia and hypoproteinemia, elevated creatinine kinase and decreased 
levels of calcium and phosphorous. Moreover, one mouse in the group treated with CPT 
was euthanized on the 51st day due to manifestation of severe toxicity. Conversely, the 
group treated with CPT-loaded FA-MSN only presented mildly elevated blood 
concentration of liver enzymes [140-141].  
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In another MSN-based model, MSNs were functionalized with hyaluronic acid (MSN-HA) 
to overcome agglomeration issues. The cellular experiments showed that MSNs-HA is 
capable of selectively targeting specific cancer cells over-expressing the CD44 protein, 
leading to rapid and concentration dependent uptake by the cancer cells through the 
receptor-mediated endocytosis mechanism [142]. Subsequently, CPT was encapsulated 
in the pores, and the system showed enhanced cytotoxicity to HeLa cells compared to 
both free CPT and CPT-loaded MSNs-HA in the presence of excess free HA. 
The integration of functional organic fragments into the framework of mesoporous silica 
to produce periodic mesoporous organosilica materials (PMOs) was reported in 1999 by 
three different groups [143-145], by using bridged organoalkoxysilane precursors 
(R’O)3Si-R-Si(OR’)3 (R: organic group). PMOs feature molecularly organic-inorganic 
hybrid compositions where the organic R moiety homogeneously distributes within the 
whole framework without blocking pore channels. The recent development shift from bulk 
materials to nanosized PMOs has resulted in mesoporous organosilica nanoparticles 
(MONs) with biomedical applications [146]. As a consequence of this hybridization 
strategy the chemical nature of the silica framework can be significantly altered, offering 
a number of specific biological effects and functions suitable for biomedicine, as tunable 
biodegradation and improved biocompatibility. However, with regards to MSNs, the in 
vivo evaluation of the biological effects and the biosafety of MONs is still in its infancy, 
and complete studies of biodistribution, excretion, biodegradation, and toxicity are still 
pending [147]. In this context, in a singular study, monodisperse MONs co-doped with 
fluorescence resonance energy transfer (FRET) cascades composed of fluorophores 
anthracene (Anth), naphthalimide (Naph) and biphenyl (Biph) at various ratios were 
prepared by a modified Stöber method, and CPT was loaded inside the pores [148]. 
Next, release experiments in PBS demonstrated that sample containing the three 
fluorophores (Biph/Anth/Naph) presented quicker release profile than samples with two 
fluorophores (Biph/Anth) or with only Biph. Actually, this CPT tunable retention ability is 
29 
 
governed by the quantity of incorporated fluorophores and their polarities, which follows 
the order of Naph > Anth ~ Biph. Moreover, although the release rate can be more finely 
tuned in an asynchronous way (a single drug) by varying the ratio between fluorophores, 
it also possible monitoring the synchronous discharge of several drugs. In this sense, it 
can be said that drug releasing performance of MONs can be well correlated with its 
color. Studies on the cellular uptake efficiency were carried out on HeLa human cervix 
carcinoma cell line, resulting that by varying the ratio between the different fluorophores, 
a colorful bioimaging system benefited from FRET should be obtained. Also, the cell 
viability evaluated using MTT assay indicated similar growth inhibition potential for MONs 










Fig. 9. Illustrations (A, D, and G), emission spectra (B, E and H) and TEM images (C, F 
and I) of monodisperse mesoporous organosilica nanoparticles co-doped with FRET 
cascades composed of triple fluorophores: anthracene (Anth), naphtalimide (Naph) and 
biphenyl (Biph). The red plus sings indicate the maximum absorption wavelength of 
different fluorophores. (Reprinted from ref. 148. Copyright © 2012 American Chemical 
Society) 
 
Closely related to MSNs, mesoporous bioactive glass nanoparticles, with higher specific 
surface area and pore volume than conventional bioactive glasses, have been recently 
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proposed for hybrid DDS development [149]. In a significant study, the mesoporous 
bioactive glass SiO2−CaO−P2O5,(MBG-OH) was functionalized with folic acid and 
fluorescein isothiocyanate silanes (MBG-FA) and, subsequently, CPT was absorbed 
within the pores (MBG-CPT) [57]. In vitro testing over HeLa human cervix carcinoma 
cells, which are overexpressed folate receptors, and L929 murine fibroblast cells, which 
are deficient folate receptors, suggested that while loading efficiency was better for FA 
free nanoparticles, MBG-CPT showed higher cytotoxicity in HeLa cell line than MBG-OH 
because of the increased cell uptake of anticancer drug delivery vehicles mediated by 
the FA receptor. Confocal microscopy experiments confirmed that nanoparticles enter 
the cells by endocytosis and that cell uptake was mediated by the folate receptor. 
Conversely, stable hybrid DDSs can also be obtained by modification of an organic 
matrix with inorganic components. In an illustrative example, silane-modified amphiphilic 
chitosan was synthesized by anchoring a coupling agent, (3-aminopropyl)triethoxysilane, 
to an amphiphilic carboxymethyl-hexanoyl chitosan. Further self-assembly in a CPT 
solution led to drug loaded nanovesicles with stable polygonal geometry, consisting of 
ordered silane layers of 6 nm in thickness [150]. The hybrid presented well-controlled 
encapsulation and release profile for CPT, which are strongly conditioned by chemical 
composition and silane concentration. These nanovesicles exhibited excellent 
biocompatibility and cellular internalization capability in ARPE-19 human retinal 
pigmented epithelium cell line, confirming by confocal microscopy experiments that 
nanomaterial entered the cytosolic compartment to release the cargo. Unfortunately, no 
cytotoxicity study comparing with the naked drug was provided. 
In another organic-inorganic model CPT was first incorporated into micelles derived from 
negatively charged biocompatible surfactants, such as sodium cholate, and these 
negatively charged micelles were then encapsulated in nanoparticles of magnesium–
aluminum layered double hydroxides (LDHs) by an ion exchange process [151]. The 
encapsulation method allowed for an approximately 3-fold increase in CPT solubility. 
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When administered to 9L Glioma cells, the nanobiohybrid containing CPT resulted in 
significantly lower survival times compared to untreated cells, or to cells incubated with 
the surfactant, the pristine LDH, or water (delivery medium). In addition, LDH surface 
modification with bifunctional succinimidyl compounds allows the attaching of active 
targeting biomolecules, which may direct these nanohybrids towards specific cells or 
subcellular components, increasing their cell uptake ratio. Although these 
nanocomplexes showed slightly lower cytotoxic activity than free CPT, they look like a 
promising biocompatible model for CPT delivery, allowing drug administration in a dose-
controlled fashion due to the good dispersion of the complexes in water.  
 
3.2.2. Core-shell systems 
Complex nanoscopic core–shell architectures are potentially useful for biomedical 
applications, for example, as image developers, smart sensor materials or as DDSs 
[152]. In this context, the target of designing multifunctional nanoparticle architectures 
for biomedical applications has strongly stimulated progress in synthesis of core–shell 
nanoparticles with increasing structural complexity. The incorporated functionalities may 
provide high resolution imaging and sensing (e.g., using fluorescent molecules, 
semiconductor nanocrystals and/or metal nanoparticles), accurate local temperature 
manipulation in cancer hyperthermia (magnetic nanoparticles, plasmonic nanoparticles), 
and controlled drug delivery and release, combining organic and supramolecular 
chemistry with colloidal nanoscience. Here, different models for delivery and controlled 
release of CPT have been reported, the most significant of which are described below.  
Core-shell organic nanocapsules for oral delivery of camptothecin were formulated with 
a core made of amphiphilic cyclodextrins (CDs) and an external coating of chitosan (CS) 
[153]. These formulations were in the range of 180-220 nm, with narrow size distribution. 
CPT was loaded in the inner polymer and then positively charged chitosan was added 
to cover the particles. The resulting nanocapsules were found to be stable in simulated 
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gastrointestinal media and proved favoring CPT permeability through an artificial mucus 
gel layer and through Caco-2 (human colorectal adenocarcinoma cells) membrane. In 
vivo animal studies in CD1 female mice demonstrated that CPT-loaded CD@CS 
nanocapsules promoted drug absorption at the intestinal tract vs stomach uptake. This 
could be an interesting vehicle for CPT oral administration, although it does not solve the 
important issue of systemic toxicity.  
One of the most studied core-shell systems is that obtained by protecting a metal 
nanoparticle with an organic coating. In one representative example, multifunctional 
nanocarriers of gold nanoclusters as core and folate (FA)-conjugated amphiphilic 
hyperbranched block copolymer (based on poly(L-lactide) inner arm and FA-conjugated 
sulfated polysaccharide outer arm) as shell, were synthesized for CPT targeted delivery 
(Fig. 10) [154]. These nanocarriers presented a release pattern curve at different pH in 













Fig. 10. Schematic illustration of gold nanoclusters as core and folate (FA)-conjugated 
amphiphilic hyperbranched block copolymer as shell. (Reprinted with permission from 




(up to 15 h), and then reached a plateau. Cytotoxicity studies over HeLa cells showed 
that, with regards to the free drug, CPT-loaded nanocarrier provided slightly higher 
(about 10%) anticancer activity, also gaining specificity to cancer cells with 
overexpressed FA receptor moieties. 
Fully inorganic core-shell hybrids can also be used for CPT delivery. In a most usual 
configuration, the nanocarrier is obtained by coating a metal nanoparticle with a silica 
outer layer, CPT being encapsulated inside the silica pores. In this sense, recently, our 
group carried out combined chemo and photothermal therapy in in vitro testing by means 
of multifunctional nanoparticles formed by plasmonic gold nanoclusters (GNCs) with a 
protecting shell of porous silica that contains CPT (GNC@SiO2) [155]. This 
therapeuticnanoplatform associated the optical activity of small GNCs (longitudinal 
surface plasmonresonance peak, LSPR, at 660 nm) to the cytotoxic activity of CPT 
simultaneously released for the efficient destruction of cancer cells. A method was used 
for the controlled assembly of 15 nm diameter gold colloids into stable clusters with a 
tailored absorption cross-section in the vis/NIR (near-infrared spectroscopy) spectrum 
(Fig. 11). Clusters were further encapsulated in an ordered homogeneous mesoporous 
silica coating that incorporates CPT molecules within the pores. After internalization in 
42-MG-BA human glioma cells, GNC@SiO2 were able to produce effective 
photothermolysis under femtosecond pulse laser irradiation of 790 nm. Moreover, the 
simultaneous release of CPT during the process increased cell death up to 70%. On the 
other hand, control experiments with no irradiation reported 45% cell death for CPT-
loaded GNC@SiO2 nanoparticles and 30% cell death for the free drug. This therapeutic 
model could be of interest for application in the treatment and suppression of non-solid 
tumors like glioblastoma multiforme. 
In a similar way, mesoporous silica-coated gold nanorods (GNR@SiO2) can find 
applications in cancer therapy due to their optical properties (LSPR at 770 nm) and 
cytotoxic activity (CPT loading in the mesopores). Moreover, tLyP-1, a kind of tumor 
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homing and penetrating peptide, was engrafted to GNR@SiO2 [156]. The obtained 
GNR@SiO2−tLyP-1 was loaded with CPT and tested over hMSC human mesenchymal 
stem cells, HeLa human cervix carcinoma and MCF-7 human breast cancer cell lines. 
After cell internalization, core-shell nanorods were irradiated by NIR illumination. Then, 
all cells were killed instantaneously by the increase in temperature caused by 
GNR@SiO2−tLyP-1 surface plasma resonance and CPT cytotoxic activity. Moreover, the 
systematic toxicity of CPT on human mesenchymal stem cells was minimized, because 
the GNR@SiO2−tLyP-1 selectively targeted and penetrated into the tumor cells, and little 










Fig. 11. (A) Schematic of synthesis and controlled aggregation of gold colloids protected 
with a thin silica layer into gold nanoclusters (GNC@SiO2). (B) UV-vis/NIR absorbance 
spectra of gold nanoclusters obtained at different NaOH concentration. (C) Photograph 
of the different colloidal gold dispersions. (D) Fluorescent microscope images of 42-MG-
BA human glioma cells incubated with GNC@SiO2 (with and without CPT) after laser 
irradiation. A control with no nanoparticles (NP) is also shown. (Adapted from ref. 155 






3.2.3. Metal organic framework nanoparticles 
Due to their porous ordered structure and virtually infinite combinations of metals and 
ligands, metal-organic frameworks (MOFs) can exhibit exceptionally high surface areas 
with large pore sizes. Consequently, they have been recently proposed for applications 
in loading and controlled release of several drug molecules [157]. However, MOFs need 
to be scaled down to the nanoregime to form nanoscale metal-organic frameworks 
(NMOFs) to be used as delivery vehicles for imaging agents and drug molecules [158]. 
NMOFs possess some potential advantages over existing nanocarriers given their 
compositional and structural diversity, which allows for the synthesis of different shapes, 
sizes and chemical properties, and their biodegradability, a result of relatively labile 
metal-ligand bonds. Surprisingly, despite the huge potential of these nanomaterials for 
novel DDSs development, stability in physiological fluids determination and identification 
of potential hazards associated to their components are still a matter to investigate [159]. 
Very few toxicological studies concern NMOFs, usually limited to specific cell lines, which 
makes it difficult to compare the results obtained. In this context, there are very few 
examples of MOF application to CPT delivery yet, most of them focused on the structure 
of ZIF-8 [160,161]. 
A general synthetic route was optimized to encapsulate several small molecules, 
including fluorescein and CPT in monodisperse zeolitic imidazolate framework-8 (ZIF-8) 
uniform of 70 nm particles with single-crystalline structure (Fig. 12) [160]. Evaluation of 
fluorescein-encapsulated ZIF-8 nanospheres in MCF-7 human breast adenocarcinoma 
cell line demonstrated cell internalization and minimal cytotoxicity. The 70 nm particle 
size facilitates cellular uptake, whereas ZIF-8 framework easy dissociation results in 
quick endosomal release of the small-molecule cargo. Here, it was shown that 
encapsulated CPT ZIF-8 particles show enhanced cell death, which involves cell uptake 









Fig. 12. Schematic illustration of MOF application for small molecule delivery (fluorescein 
in green (A) and CPT in blue (B)) inside of ZIF-8. CPT molecule fits well within the 
microporous framework, which loads a maximum of 2 % drug. (Reprinted from ref. 160. 
Copyright © 2014 American Chemical Society) 
 
Overall, the incorporation of CPT to a nanocarrier definitively improves its therapeutic 
efficacy. All vehicles provide a clear increase of drug stability, as the encapsulated or 
bonded molecule is protected from enzymatic degradation and lactone ring cleavage 
during its transit through blood stream and tissues to tumor location. Moreover, colloidal 
stability of these formulations can boost drug solubility several orders (e.g., β-
cyclodextrins), which gathered to the stability rise improves the bioavailability. However, 
the most significant effect of incorporating CPT into a nanocontainer is the dramatic 
toxicity reduction and therapeutic window extension, as the transported molecule has 
very little activity before it is discharged at the tumor place. As a consequence, the in 
vivo antitumor activity increases with regards to the free drug, due to an improved 
bioavailability and the possibility to increase the dose with no side effects. In addition, 
many of these nanomedicines offer the possibility of delivering several drugs in a row, 
which is very important for the treatment of MDR cancer, and allow for the incorporation 
of targeting molecules that favor selective therapy. Finally, inorganic and hybrid materials 
can present unique properties (e.g., optical activity, magnetism, semiconductor activity), 




4. Stimuli responsive systems 
These are currently the most representative DDSs in Nanomedicine. The main 
characteristic is their ability to deliver a therapeutic agent into the target cells with no 
previous release. This is due to the accurate control of the release process through a 
specific intracellular stimulus, which minimizes undesired side effects. Stimuli-
responsive nanocarriers can be classified in endogenous or exogenous, depending on 
the stimulus which activates the drug release mechanism. Examples of endogenous 
stimuli are pH, redox potential and enzyme activity. On the other hand, classical 
exogenous stimuli include magnetic fields, ultrasounds, light and temperature [162-165].  
 
4.1. pH-sensitive systems 
Several pH-sensitive DDSs have been developed based on the pH difference between 
normal and tumor tissue. Here, some of these platforms take advantage of the fact that, 
in some cases, tumor tissue pH profile is slightly lower than normal tissue. However, the 
heterogenicity of extracellular pH both within and between tumors poses a significant 
challenge, as low extracellular pH regions are likely to be less accessible to nanoparticles 
that do not distribute readily within the tumour interstitium. This factor, together with the 
lower pH values inside endosomes, suggests that enhancing endosomal escape is the 
most realistic objective for pH-sensitive nanocarriers in the short term [166].  
Polymeric, pH-responsive micelles have been prepared by a solvent evaporation 
method. For this purpose, hydrophilic methyl ether poly(ethylene glycol) (MPEG) and 
biodegradable poly(β-amino ester) (PAE) were copolymerized to give MPEG-PAE block 
copolymer (Fig. 13). Then, CPT was encapsulated into the micelles (CPT/MPEG-PAE) 
through hydrophobic interactions between drug and PAE. At pH 6.4-6.8 CPT/MPEG-
PAE were demicellized and the encapsulated CPT was rapidly released from these 
nanocarriers, although under pH 7.4 the release rate was clearly slower. In vitro 
cytotoxicity assays in MDA-MB231 human breast tumor cells confirmed that these 
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micelles provoked severe cytotoxicity within an acidic environment due to rapid CPT 








Fig. 13. (A) Chemical structure of methyl ether poly (ethylene glycol) - poly(β-aminoester) 
block copolymer (MPEG-PAE). Letters x and y indicate the number of times that the 
block polymer is repeated. (B) Schematic diagram of pH-responsive CPT/MPEG-PAE 
micelles at weakly pH condition. The figure shows CPT in blue, and in red and yellow 
the MPEG-PAE block copolymer. (C) Size distribution of MPEG-PAE micelles in PBS at 
pH 7.4 by dynamic light scattering (inset: TEM image). (Reprinted from ref. 167, 
Copyright © 2010, with permission from Elsevier) 
 
Another pH-sensitive nanoscaled system for CPT delivery has been obtained by 
conjugation to a biocompatible, hydrophilic copolymer of mucic acid and polyethylene 
glycol (MAP). When this polymer-drug conjugate was placed in water, it self-assembled 
into MAP−CPT nanoparticles of ca. 30 nm [168]. Then, antibody herceptin was 
complexed with MAP-CPT to form a targeted nanoparticle. A strong dependence of 
release rate with pH was observed but, unlike the standard behavior, as pH increased 
from 6.5 to 7.4, the release half-live dropped from 338 to 58 h for MAP−CPT 
nanoparticles. In vitro testing over BT-474 and HER2 human breast cancer cell lines 
showed that cellular uptake of nanoparticles was enhanced by 70%, compared to non-
targeted version, by the incorporation of a single herceptin antibody molecule per 
nanoparticle. Moreover, CPT was released from MAP-CPT nanoparticles by hydrolysis 
and nanoparticle disruption by fat. The targeted MAP-CPT nanoparticle system carried 
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ca. 60 CPT molecules per nanoparticle and showed prolonged plasma circulation with 
an elimination half-life of 21.2 h and AUC value of 2766 μg h/mL at a 10 mg CPT/kg tail 
vein injection in female BALB/c nude mice. 
Encapsulation of CPT in micelles with a hydrophilic shell of chitosan and a hydrophobic 
core of poly(p-dioxanone) has been also used to control drug release on the basis of 
environment pH changes [169]. CPT was incorporated in the core of this system and its 
release was triggered at pH 7.4, 6.2 and 5.0. In vitro drug release studies in HeLa human 
cervix carcinoma and L929 mouse fibroblast cells demonstrated that the micelles 
presented a much faster release of CPT at pH 5.0 than at pH 7.4, whereas blank micelles 
without CPT were found to be nontoxic in both cell lines. The good internalization effect 
of these micelles was explained by the electrostatic interactions between positively 
charged micelles and cell membranes.  
In another recently published study, an inorganic pH-sensitive nanocarrier was able to 
deliver different chemotherapeutic drugs simultaneously for a better synergetic effect. 
This nanoplatform was based on hollow silica nanoparticles sealed with ZnO quantum 
dots (QDs). Subsequently, CPT was encapsulated in the hollow core through 
hydrophobic interactions. On the other hand, doxorubicin (DOX) was deposited on the 
mesoporous shell via electrostatics interactions with carboxylate groups incorporated on 
the mesoporous surface [170]. This cooperative drug loading largely increased drug 
encapsulation efficacy of both CPT and DOX up to 89.28% and 44.98%, respectively. 
Drug release was compared at pH 7.4 and pH 5.0, concluding that in acid medium the 
amount of discharged drugs was higher due to ZnO QDs disintegration.  
 
4.2. Redox-sensitive systems 
It is well-known the difference in redox potential between the oxidizing extracellular 
space and reducing intracellular space, which is related with glutathione (GSH) 
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concentration. This fact has found application in the building of specific DDSs able to 
selectively discharge their therapeutic load after cell uptake. Here, drug covalent linking 
to nanocarriers is mostly carried out by disulfide bridge, which makes possible to design 
of different sensitive systems. The main concern for in vivo application of these systems 
is the presence of GSH in serum which, despite the fact that its concentration is less than 
one order below that of cytosol, may provoke some premature release during CPT transit 
at blood stream [171]. 
Hybrid micelles subjected to redox-responsive cleavage have been developed by cross-
linking CPT-loaded organic units with disulfide bonds [172]. These micelles were 
obtained via coprecipitation of disulfide-containing CPT-poly(tyrosine(alkynyl)-O-
carboxyanhydride) conjugate and monomethoxy poly(ethylene glycol)-b-
poly(tyrosine(alkynyl)-O-carboxyanhydride), followed by cross-linking of the micellar 
core via click chemistry (Fig. 14). In this case, CPT was rapidly released due to the 
elevated concentration of cytosolic glutathione that disorganizes micelle structure by 
disulfide bond cleavage, which is present both in the CPT prodrug and the cross-linker. 
In vitro cytotoxic assays against MCF-7 human breast cancer cells suggested high 
anticancer activity due to the disassembly of the cross-linked micelle and rapid CPT 
release.  
Also recently, our group implemented a new synthetic strategy by direct coupling of as-
synthesized (pyridin-2-yldisulfanyl)alkyl carbonate derivatives of CPT with thiol groups 
of silica hybrid nanoparticles containing a non-porous core and a mesoporous shell [173]. 
Upon reaction with thiols in physiological conditions, disulfide bridge cleavage occurs, 
releasing the naked drug after an intramolecular cyclization mechanism (Fig. 15). 
Additional incorporation of a fluorophore into particles core facilitated imaging at the 
subcellular level for the monitoring of uptake and delivery. Confocal microscopy 













Fig. 14. Schematic procedure for preparation of redox-responsive uncross-linked (UCL) 
and core-cross-linked (CCL) hybrid micelles. (Reprinted partially with permission from 
ref. 172. Copyright © 2013 American Chemical Society) 
 
the cells by endocytosis but are able to escape from endo-lysosomes and enter the 
cytosolic compartment to release their cargo by glutathione reducing activity. Moreover, 
in a separated study [174], it was shown that prodrug side chain carbon number (n) 
determines material hydrophobic properties and, as a consequence, its stability in 
aqueous medium and cell uptake kinetics. When n value increases, the negative surface 
charge decreases dramatically due to a shielding effect provoked by hydrophobic 
ligands, which promotes particle aggregation and favors cell internalization. 
Furthermore, n value also determines the type of products released and, subsequently, 
the cytotoxic activity. Although full disulfide bridge reduction occurs in all cases within 
the cell, the subsequent intramolecular cyclization releasing CPT, CO2 and the 
corresponding thiolactone only happened quantitatively for n=1 (Fig. 15), whereas higher 














Fig. 15. Redox-responsive nanoplatform for CPT delivery by direct coupling of (pyridin-
2-yldisulfanyl)alkyl carbonate CPT derivatives with thiol groups of silica hybrid 
nanoparticles containing a non-porous core and a mesoporous shell. Upon reaction with 
thiols in physiological conditions, disulfide bridge cleavage occurs, releasing the naked 
drug after an intramolecular cyclization mechanism. (Adapted from ref. 173, with 
permission of The Royal Society of Chemistry) 
 
A supramolecular strategy was reported to directly assemble the hydrophobic CPT 
molecule to a β-sheet-forming peptide sequence derived from the cysteine-containing 
au protein through the reducible disulfylbutyrate (buSS) linker, obtaining discrete, stable, 
well-defined nanostructures with a high and quantitative drug loading [175]. Drug content 
was precisely controlled using the two amine functionalities of the amino acid lysine to 
create branching points that allow the attachment of one, two or four CPT molecules, 
corresponding to respective drug loadings of 23%, 31% and 38%. Depending on the 
number of CPT molecules in the supramolecular design, the resulting nanostructures 
can be either nanofibers or nanotubes. Such nanostructures provide CPT protection from 
the external environment. Release profiles showed that glutathione degraded the 
designed buSS linker, releasing a mixture of intermediates and CPT.  Under tumor-
relevant conditions, these drug nanostructures released the active form of CPT and 
showed in vitro efficacy similar to free CPT against MCF-7 human breast cancer cells 
and 9L and F98L rat gliosarcoma cell lines. In addition, to avoid the formation of 
mesoporous silica
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intermediates, the same researchers prepared these CPT-nanostructures using a 
(disulfanyl)ethyl carbonate linker, that after disulfide bridge reduction by glutathione 
followed a self-immolative process to release free CPT, improving cytotoxicity over MCF-
7 cell line [176]. Furthermore, in vivo preliminary experiments, after intratumoral injection 
with 36% CPT loaded sample over 6-8 week female BALB/c mice bearing subcutaneous 
CT26 murine colorectal adenocarcinoma, showed higher enhanced retention time of 
CPT nanotubes in the tumor site than the free molecule, which allows a sustainable 
release over a long period [177]. Conversely, no improvement in tumor targeting was 
detected with the nanomedicine in case of administration by tail vein, so the potential of 
this impressive nanoconjugate as DDS is still to be confirmed. 
 
4.3 Enzyme-sensitive systems 
In these drug delivery nanoplatforms, the therapeutic molecule is engaged to 
nanoparticles by a covalent bond that may be cleavage by enzymatic activity. Enzyme-
responsive nanomaterials facilitate the targeting of specific tissue by programming drug 
release via enzymatic digestion of the nanocarrier or linking moiety [178]. The biological 
recognition of the substrate by the enzyme leads to the selective and specific triggering 
event to release the cargo, which minimizes toxicological issues related to CPT. In this 
context, due to the high concentration of carboxylesterases in the cytosol, most of these 
models have been developed over the basis of an ester bond at 20-OH position between 
CPT and the nanostructured surface. On the other hand, there are two main 
shortcomings in the use of enzyme-responsive devices for CPT delivery: i) the presence 
of carboxylesterases in plasma may motivate some nonspecific release outside the 
tumor cells, and ii) the binding of CPT to a nanoparticle surface can limit the accessibility 
to enzyme active site due to steric effect, slowing down the release process, which 
reduces the cytotoxic activity [179]. 
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In a singular approach, CPT molecules were directly grafted to carboxyl groups of poly(L-
glutamic acid) (CPT-PGA) through ester bond [180]. Subsequently, a supramolecular 
nanoparticle system was obtained by conjugation of CPT-PGA with several polymeric 
derivatives (Fig. 16). This system released CPT under physiological conditions by means 
of esterase-mediated hydrolysis. Cell viability assays in MCF-7 human breast cancer 
cells indicated nanoparticle delivery system IC50 was 4 times that of the free drug, 
probably due to the slow release of CPT from polymer. However, a positron emission 
tomography study with 64Cu-labeled nanoparticles in C57Bl/6 mice bearing Lewis lung 
carcinoma tumors revealed significant tumor specific uptake of nanoparticles. Moreover, 
in tumor reduction/inhibition studies these nanomedicines showed much higher efficacy 










Fig. 16. Schematic representations of the self-assembly and synthesis of 
supramolecular nanoparticles by conjugation of CPT-grafted poly(L-glutamic acid) with 
different polymeric derivatives. Legend: Ad-PEG=poly(ethylene glycol); CD-PEI= 
cyclodextrin-poly(ethylenimine); Ad-PAMAM=poly(amido)amine (Reprinted from ref. 
180, Copyright © 2012, with permission from Elsevier) 
 
Conversely, CPT conjugation to nanoparticles by ester bond is usually performed in two 
steps. First, a prodrug is prepared by esterification with a short linker and then, this 
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prodrug is covalently linked to a supramolecular structure. For instance, to incorporate 
CPT into PAMAM, CPT was firstly substituted at 20-OH position with glycine through 
ester bond and, afterwards, the prodrug was reacted with PAMAM G4, to give PAMAM-
CPT [181]. This material was stable in plasma and the presence of proteolytic enzymes 
such as cytosolic esterases promoted conjugate cleavage and CPT release. Cell 
internalization and in vitro assays of this nanomedicine in HTC-116 human colorectal 
cancer cells indicated a high cytotoxic effect due to nuclear fragmentation and formation 
of apoptotic bodies.  
 As a different model, our group recently prepared a hybrid organic-inorganic silica 
nanoplatform for CPT delivery based on enzyme-triggered release. For this sake, CPT 
was covalently linked to nanoparticles through an ester bond with the 20-hydroxy moiety, 
in order to stabilize its lactone ring and to avoid unspecific release of the drug [179]. The 
obtained material was highly stable in plasma, with less than 5% release of the cargo at 
physiological pH. Cell internalization and in vitro efficacy assays against HeLa, U87-MG 
human primary glioblastoma cell line, HCT-116 human colon carcinoma and HT-29 
human colorectal adenocarcinoma cells, demonstrated that nanoparticles carrying CPT 
(SNP-CPT) entered cells via endocytosis and the intracellular release of the cargo 
induced cell death with half maximal inhibitory concentration (IC50) values and cell cycle 
distribution profiles similar to those observed for the naked drug. Furthermore, in vivo 
biodistribution, therapeutic efficacy and biocompatibility of the SNP-CPT were evaluated 
in hsd:athymic nude-Foxn1 mice bearing HT-29.Fluc subcutaneous tumors, showing 
that, although SNP-CPT tended to accumulate in organs of the reticulo-endothelial 
system, nanoparticles delayed the growth of subcutaneous tumors while significantly 































Fig. 17. Tumor growth delay in hsd:athymic nude-Foxn1 mice bearing HT-29.Fluc 
subcutaneous (s.c.) tumors. (A) Comparative analysis of the localized s.c. growth of the 
HT-29.Fluc tumors untreated (PBS) and treated (CPT or SNP-CPT) in hsd:athymic nude-
Foxn1 mice by external measurement (caliper) of tumor volume. (B) In vivo monitoring 
of a representative mouse from each treatment group shows radical tumor growth 
reduction with regards CPT and the control group. (Reprinted partially from ref. 179, 
Copyright © 2011, with permission from Elsevier)  
 
4.4. Light-sensitive systems 
In addition to chemically-triggered delivery systems, remote activation of nanoparticles 
by light for biomedical applications has become an important field of research [182].  This 
type of stimuli-responsive nanoplatforms present a component sensitive to ultraviolet 















































(UV), visible (Vis) and/or near infrared (NIR) light which is able to activate drug release 
under irradiation. As an exogenous stimulus, the main advantage of light over 
endogenous processes is the possibility to accurately modulate stimulation that controls 
drug release. In this sense, light is not only noninvasive but also controllable both 
spatially and temporally, allowing for greater safety and specificity [183]. Conversely, low 
penetration ability and predominant use of UV and visible light limit the clinical potential 
of these systems. So far, many different systems have been described, involving 
photocleavage, photodissociation, photoisomerization, photorelease, photothermal, 
photo-plasmonic heating, and up-conversion photoisomerization [184]. 
In a pioneering work, a nanoimpeller-controlled mesostructured nanoparticles was 
developed to deliver and release CPT into living cells upon light activation [185]. These 
light-triggered MSNs were functionalized with azobenzene moieties in the pore interiors, 
with one end attached to the pore walls and the other end free to undergo 
photoisomerization. The impeller in the nanopores trapped drug molecules in the dark, 
and release them in response to UV light (413 nm) excitation (Fig. 18). In vitro studies in 
PANC-1 human pancreatic and SW480 human colon cancer cell lines showed the 
photoresponsive behavior of the impeller inside of cells. After 3 h of incubation in the 
dark, the cells were irradiated with ~0.1 W cm-2, 413 nm light, for various excitation times 
(0 to 10 min). Cell death was induced under photocontrol. In the absence of light 
excitation, the CPT remained in the particles and cells were not damaged. However, 
illumination promptly expelled CPT from the particles, causing cancer cell apoptosis, 
which is demonstrated by nuclear fragmentation and chromatin condensation. 
Unfortunately, the application of UV/Vis light in biomedical studies is mostly limited to 
proof-of-concept, because irradiation at this wavelength can damage cells and does not 
penetrate deep inside the tissues. However, using two-photon excitation (TPE) in the 










Fig. 18. Schematic illustration of the light-activated mesostructured silica nanoparticles 
functionalized with azobenzene derivatives in the pore interiors. (Adapted with 
permission from ref. 185. Copyright © 2008 John Wiley and Sons) 
 
losses and three-dimensional spatial resolution. For this sake, the former nanoimpeller-
controlled MSNs device was functionalized with a high absorption cross-section two- 
photon fluorofore, suitable for Forster resonance energy transfer (FRET) to 
photoizomerize azobenzene moieties in the NIR region [184]. The two-photon absorption 
properties of the fluorophore were retained in the materials and no decrease of cross-
sections σ2 was noticed after encapsulation. The nanoimpeller groups pending in the 
porous framework allow the physical entrapment of CPT, which is then kicked out of the 
pores by two-photon-triggered photoisomerization. Therefore, the nanoimpellers were 
loaded with CPT and then screened under TPE in MCF-7 human breast cancer cells. 
Cells were incubated with nanoparticles and further irradiated in at very short time with 
a focused laser beam (input 3 W, output 900 mW cm-2). The MTT assay was performed 
two days after irradiation. Nanoimpellers loaded with CPT and high 
fluorofore/azobenzene ratio significantly increased cancer cell death under TPE in 
comparison to no irradiation. 
Another representative light-responsive prototype was developed as a self-deliverable 
form of nucleic acid-CPT nanostructure (DNA-CPT) that is composed almost entirely of 
payload molecules [186]. To tackle this strategy, three CPT molecules were attached to 
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a phenol group connected to a photolabile 2-nitrobenzyl ether moiety. This photolabile 
group was linked to a DNA strand to obtain an amphiphile, which self-assembled in DNA-
CPT nanostructure. Under UV irradiation (365 nm), the 2-nitrobenzyl was cleaved, 
releasing the DNA from the conjugate and leaving a decapped self-immolative drug core, 
which, afterwards, underwent a rapid, spontaneous and irreversible degradation process 
to release free CPT molecules. In vitro efficacy assays in SK-BR-3 human breast cancer 
cell line confirmed that cytotoxicity of DNA-CPT nanostructure increased significantly by 
light triggering, achieving IC50 values similar to those observed with the naked drug. 
In a different strategy, the surface of MSNs may be modified in order to deposit a 
hydrophobic layer able to monitor drug delivery by adjusting the wetting of particle 
surface. In this context, a light-sensitive release system based on a hybrid with MSN 
core and spiropyran and perfluorodecyltriethoxysilane coating was built [187]. Particles 
are protected from being wetted by water at the optimal ratio of spiropyran to fluorinated 
silane (0.249:1), which successfully inhibits drug release. Upon irradiation with UV light 












Fig. 19. Schematic presentation of the light-sensitive release system based on 
mesopororus silica nanoparticles surface functionalized with spiropyran and 
perfluorodecyltriethoxysilane in an optimal ratio. Under UV irradiation at 365 nm, 
spiropyran was converted to the hydrophilic form, which resulted in the wetting of surface 
of MS and the release of trapped molecules diffusing from the penetrated water. 




state caused the surface to be wetted, leading to the release of encapsulated CPT from 
the pores (Fig. 19). In vitro experiments in EA.hy926 human somatic cell hybrid and HeLa 
human cervix carcinoma cells demonstrated an accurate drug controlled release. Here, 
CPT loaded nanoparticles (10 mg/g) were incubated in cells for 24 h and then, upon UV 
light irradiation a noticeable loss of cell viability was observed with regards to non-
irradiated cell cultures or with no nanoparticles. 
 
4.5. Magnetic-sensitive systems 
Magnetic gradients may be used to target therapeutics to specific tissues, while 
alternating magnetic fields produce frequency-dependent effects at the nanoparticle 
level. This type of nanocarriers implicates para-magnetic or super-paramagnetic 
materials which are embedded into organic polymeric moieties, allowing the release of 
the drug under an external magnetic stimulus. The inorganic component is designed to 
impart responsivity to external magnetic fields, both static and dynamic, in order to 
impose a remote magnetic control of drug cargo release. Furthermore, soft matter 
architectures provide a very convenient structural scaffold for insertion of therapeutic 
principles [188]. Nevertheless, as commented before (section 3.2), the most serious 
concern about the use of magnetic nanoparticles within therapeutic formulations is their 
biocompatibility, especially in the long term. In particular, their stability when introduced 
within the body is a crucial aspect, as the proper dispersion and circulation of 
nanoparticles strongly affect drug release kinetic, accumulation, and toxicity. Actually, 
SPIONs are the only engineered inorganic nanoparticles approved for human use. 
One of the most illustrative drug delivery models of hybrid magnetic materials is based 
on MSN pore capping with iron oxide nanoparticles [189]. This may be preferentially 
done through chemical bonding. For this sake, MSNs surface was funtionalized with 3-
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aminopropyltrimethoxy silane groups. Afterwards, CPT was filled into the pores and 
these were covalently capped through amidation of the 3-aminopropyl groups at surface 
with meso-2,3-dimercaptosuccinic acid functionalized superparamagnetic iron oxide 
nanoparticles [190]. The Fe3O4 nano-caps formed a dense and uniform layer tightly 
bound to the MSN surface (MSN@Fe3O4). Under magnetic stimulus, the cumulative drug 
release was very quick, and prolonged even when the stimulus was removed, due to 
detachment of some Fe3O4 nanoparticles (Fig. 20). Such a magnetically-induced 
removal of the nano-caps implies a cleavage of the chemical bond between the Fe3O4 
nanoparticles and silanized MSNs. The energy induced from the magnetic stimulus over 
various timespans is sufficiently large to cleave the chemical bond, resulting in an 
effective removal of the nano-caps. Actually, the rate of nano-cap removal and drug 
diffusion are a function of the magnetic energy. Then, cytotoxicity studies in A549 human 










Fig 20. Schematic illustration of the synthesis and structure of mesoporous silica 
nanoparticles capped with iron oxide nanoparticles. The structure was obtained by 
capping mesoporous silica nanoparticles (MSN) with monodispersed Fe3O4 
nanoparticles through chemical bonding. Under magnetic stimulus, some of the Fe3O4 
nanoparticles were removed from the surface of the MSN, and CPT was released. On 
the right, a brief illustration of all different ligands used in the synthesis of this material. 




capped MSN effectively constrained the CPT from free elution and were well tolerated, 
resulting in a cell viability of more than 80%. However, upon magnetic stimulus, about 
42% of the cells were killed, and the major cause of cell death was the CPT released 
from the MSN@Fe3O4. 
Magnetic stimulus can also be used to accelerate drug release from core-shell hybrid 
nanoparticles constructed by self-assembly of iron oxide in the presence of polyvinyl 
alcohol. Then, CPT was incorporated to the organic component of the core, followed by 
coating with a thin layer of silica to eliminate undesirable drug leakage [191]. Here, the 
operation of an external magnetic stimulus allows a pulse-type drug release to be readily 
achieved in a real time responsive manner without undesirable delays in dosing 
accuracy. The intracellular release of CPT from nanocarriers in A549 cells was 
stimulated by high frequency magnetic field (HFMF, 2.5 kA m-1, 50 kHz) for 30-120 s. 
Upon magnetic stimulus, CPT release profile for the nanocarriers in different eluting 
media indicated that the rate of drug diffusion was considerably increased, which is due 
to thermally induced disruption of particle nanostructure [192]. Subsequently, cells were 
incubated for 18 h, and the anticancer effect was measured by MTT assay. It was found 
that CPT IC50 value measured on A549 human lung adenocarcinoma epithelial cells was 
around five times lower than that of the free drug when CPT was loaded into magnetically 
sensitive nanocarriers and released intracellularly. Moreover, a similar model was 
performed by preparation of embedded Fe3O4 nanoparticles in a PLGA core containing 
CPT, protected by a lipid–polymer hybrid shell [193]. In vitro testing of these drug delivery 
capsules in MT2 mouse breast cancer cells showed significantly suppressed cancer cell 





4.6. Other stimuli-responsive systems for camptothecin delivery 
In addition to the different stimuli-responsive systems described, in some recent studies 
other analogue entities have been proposed for CPT delivery and controlled release 
under endogenous or exogenous stimulation. We here summarize some of most 
advanced approaches. 
Thermo-responsive nanomaterials are a kind of adaptive nanoparticles sensitive to 
environmental temperature changes that may help to monitor spatial delivery of a 
therapeutic payload. Under pathological local high temperature records (for instance, 
those reported in inflammation and cancer) these systems undergo a phase transition 
and conformational change that compromise the integrity of the nanostructure and 
activate payload release. At this point, polymers can be designed in such a manner so 
that this phase transition, which is termed as the lower critical solution temperature 
(LCST), takes place at around 37 ºC. Under LCST the hydrogel nanopreparation is 
soluble for in vivo injection, but becomes insoluble and aggregated in the tumor regions 
heated above its LCST, leading to local drug discharge [194]. In this context, CPT 
thermo-sensitive DDSs can be prepared based on spherical core-shell nanoscale 
micelles. Firstly, two kinds of thermo-sensitive poly(N-isoproplacrylamide) (PNIPAM) 
four-armed star multiblock copolymers were synthesized by atom transfer radical 
polymerization. Then, the multiblock copolymers could spontaneously assemble into 
regular spherical core–shell nanoscale micelles of about 100-120 nm diameter and LCST 
of about 33-35 ºC [195]. Drug release was thermo-responsive, accompanied by 
temperature-induced structural changes of the micelles. At 37 ºC, CPT release from 
micelles is clearly quicker than at 25 ºC (respectively, 74 and 53% at 48 h) due to 
temperature-induced structural alterations of multiblock copolymers. This accelerated 
drug release above the LCST is correlated with the enhanced hydrophobicity of PNIPAM 
shells, which leads to micelle shrinkage, and makes CPT diffuse out quickly. In vitro 
cytotoxicity studies carry out by MTT assay over MDA-MB231 human breast cancer cell 
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line, demonstrated slightly lower activity for the CPT-loaded micelles than for the free 
CPT, probably due to time-consuming CPT release from the micelles. 
Ultrasounds represent another effective method for attaining spatio-temporal controlled 
release at the target cells, preventing side effects to healthy tissues. Ultrasound waves 
can trigger drug through the thermal and/or mechanical effects generated by cavitation 
phenomena or radiation forces. Here, physical forces associated to cavitation can induce 
nanocarrier destabilization, drug release and transient increase in vessel permeability, 
leading to the cellular uptake of therapeutic molecules. Acoustically active 
perfluorocarbon nanoemulsions have been proposed for CPT encapsulation, in order to 
circumvent its well-known bioavailability issues as insolubility, instability and toxicity 
[196]. The nanoemulsions were firstly prepared with perfluoropentane, perfluorohexane 
and coconut oil as the core of the inner phase, which incorporates CPT molecules. Then, 
a stabilizing coating made of phospholipids and/or Pluronic F68 was applied, obtaining 
a mean droplet diameter of 220-420 nm. For the study of ultrasound influence on CPT 
release the nanomulsion was exposed to ultrasound using a 1 MHz probe with a 1.5 
W/cm2 intensity for 2 h. However, CPT released from the nanoemulsions was limited, 
with less than 15% of the drug being discharged over 48 h. Moreover, it was found that 
droplet diameter had an influence in release rate, as the amount of exposed surface 
decreased for bigger droplets, which slows down CPT liberation. Furthermore, in order 
to simulate parenteral administration conditions, plasma was added to the 
nanoemulsions and, next, sonication with ultrasound energy was used to stimulate the 
liquid-to-gas transition of perfluorocarbons [197]. As the droplets became gas bubbles, 
they began to oscillate or resonate and, eventually, bubbles were destroyed and 
provoked a local drug release. Unfortunately, no biological study is reported with this 
interesting CPT controlled release model. 
Recently, glucose-responsive materials have attracted research interest due to their 
potential application as DDSs. Most of these systems have been developed as platforms 
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for glycemia control in diabetes mellitus patients. Among them, the most studied model 
is that based on phenylboronic acid [198]. In aqueous medium, phenylboronic acid holds 
an equilibrium between an uncharged form and a charged form. The first one is 
hydrophobic but the second form is hydrophilic. This last is able to form a stable 
phenylborate with cis-diol compounds, like glucose, which shifts the equilibrium in the 
direction of increasing the hydrophilic form. Usually, this shift is enough to increase the 
swelling degree of crosslinked nanogels or to disintegrate self-assembled micelles, 
causing the entrapped payload to be released into solution. This provides a way for 
designing polymeric carriers for self-regulated delivery not only of insulin but also of other 
therapeutic agents. For the purpose of CPT delivery, hybrid nanoparticles with iron oxide 
and mesoporous silica were loaded with the drug and further capped with a 
phenylboronic-dextran conjugate [199]. In a further step, CPT was encapsulated in silica 
mesopores followed by incubation with dextran (Mw 6000 and 100000), which bounded 
with phenylborate linker via glucose monomer 1,2-diol groups (Fig. 21). Consequently, 
dextran closes the surface of pores, preventing drug release. CPT release mechanism 







Fig. 21. Schematic procedure for preparation of glucose-responsive hybrid nanoparticles 
with iron oxide cores and dextran-gated mesoporous silica shell. The design involves the 
synthesis of magnetic mesoporous silica nanoparticles (MMS) functionalized with 
phenylboronic acid and folate. Then, CPT was loaded inside the pores of MMS, the 
outside of pores was closed by dextran via binding with phenylboronic acid. Dextran-
gated pores were opened for drug release in the presence of glucose that competes 
binding with phenylboronic acid. (Reprinted with permission from ref. 199. Copyright © 
2014 American Chemical Society) 
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phenylboronic acid. Glucose has one 1,2-cis diol group that binds strongly to 
phenylborate linker, removing the larger size dextran from pore surface. In vitro results 
over HeLa human cervix carcinoma cell line showed a significant reduction of cell viability 
in glucose containing RPMI cell culture medium, but no effect in the absence of glucose, 
showing that drug loaded particle offers glucose concentration-dependent cell viability. 
To end this section, we can summarize that stimuli-responsive systems are able to 
deliver CPT to tumor tissue and cells with minimum (or meaningless) premature release, 
imposing an efficient drug discharge inside cells under a specific stimulus. This is 
particularly important in the case of very cytotoxic molecules like CPT, as these DDSs 
increase anti-tumor activity and minimize side effects. It must be taken into account that 
for most DDSs, less than ~5% of the injected dose reaches the tumor site [161]. In this 
context, the design of nanocarriers sensitive to exogenous or endogenous stimuli 
represent a safe alternative to regular chemotherapy with CPT structural analogues. The 
main concern with most of these systems, for translation from the bench to the bedside, 
is related to their chemical complexity, as most of them are hybrid materials with organic 
and inorganic components, and several-step synthesis protocols. This hampers not only 
the scaling-up of their synthesis, but also their degradability and biocompatibility. 
Moreover, the ability of these models to be sensitive to discrete variations of pH, redox 
potential or enzyme activity is not always straightforward to achieve, whereas the scope 
of externally applied stimulus is strongly depends on the penetration depth ability. 
Nevertheless, some of these systems are on the way towards achieving clinical 
application, as it will be shown below. 
 
5. Clinical testing  
One of the most disputable arguments again nanomedicines is that, despite the strong 
publication statistics over the last decade, very few drugs have reached the commercial 
market yet [79]. Although it is accepted that nanocarriers improve solubility, efficacy and 
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biodistribution, while decreasing adverse side effects of very cytotoxic drugs as CPT, 
strict regulations concerning their use in human beings have hampered, so far, a quicker 
translation of these therapeutic platforms into the clinical stage. At this point, it must be 
taken into account that nanocarriers are evaluated for each of their components within 
the formulation, and aspects like colloid stability in biological fluids, low immunogenicity 
and long-term toxicity may not always be assessed. Moreover, the necessary refining of 
the delivery process performance is yet to be achieved [200]. In this context, only a few 
organic polymers have been approved by the Food and Drug Administration (FDA) as 
CPT delivery systems for cancer therapy. Below we describe briefly some of the most 
representative examples as well as their current position at the pipeline. All these cases 
have been compiled in Table 2. We accept that some of these DDSs might not form solid 
nanoparticles in real in vivo conditions [201], but in all cases, the methods followed for 
material preparation, drug administration, biodistribution profile study and therapeutic 
validation are fully comparable.  
CRLX101 (formerly IT-101) is a pharmaceutical polymeric nanoparticle developed at 
Calando Pharmaceuticals, Inc. composed of a cyclodextrin-PEG copolymer covalently 
linked to CPT, and was designed to enhance drug solubility and biodistribution [117]. 
The antitumor drug was released by hydrolysis of the ester bond between the 
cyclodextrin and CPT hydroxyl group at C20 position. With regards to irinotecan, this 
compound showed improved cytotoxicity against MDA-MB-231 human breast cancer 
cells, Panc-1 human pancreatic cells and HT29 human colorectal adenocarcinoma cell 
line [117,202], entering Phase Ia trial for the treatment of solid tumors over 10 patients 
in 2006. Also, a combined Phase Ib/IIa trial over 62 patients with advanced solid 
malignancies demonstrated encouraging safety, pharmacokinetic, and efficacy [203]. 
This preparation was tolerated with no evident side effects. Consequently, a Phase II 
trial was started in 2008 for therapy of 29 ovarian cancer patients and, later on, in 2011, 
a Phase II trial was launched over 157 patients with non-small cell lung cancer, in order 
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to assess the activity and safety of CRLX101. In addition, comparative preclinical studies 
suggested that CRLX101 behavior in animal models could be the same than in humans 
[204]. Actually, we should consider that, although nanomedicine accumulation in solid 
tumors by EPR effect is quite rationalized for animal models of human disease, these 
models poorly represent human tumors. Nevertheless, in a very recent study over 9 
gastric tumor patients consisting of collecting tumor and nonneoplastic tissue biopsies 
24-48 h after CRLX101 administration, evidence indicated an intact deposition of 
nanoparticles in tumor tissue in five of these 9 patients, whereas no CRLX101 trace was 
found in nonneoplastic tissue. Moreover, in all cases, sufficient CPT concentration 
reached the tumor to cause down-regulation of topoisomerase I and carbonic anhydrase 
IX [205]. 
CT-2106 is a CPT-poly-L-glutamate conjugate developed to improve the solubility and 
prevent CPT lactone ring cleavage. In this supramolecular system, CPT binds the 
glutamate polymer through esterification at 20-OH. In preclinical models, CT-2106 
showed antitumor activity against multiple tumor cell lines, such as B16 murine 
melanoma cells and H322, H460 and H1299 human lung cancer cells, and retained 
substantial anti-tumor activity in syngeneic (over C57BL/6 mice) and xenogeneic (over 
female nude mice) tumor models [206]. CT-2106 Phase I trial was started by Cell 
Therapeutics, Inc. in 2003. A dose escalation study was carried out over 24 patients with 
different advanced solid tumors [207]. The only serious related toxicity was grade 4 
hypersensitivity in a patient with a history of hypersensitivity to irinotecan. Furthermore, 
Cell Therapeutics, Inc. extended this Phase I trial in 2006. For this sake, 26 patients with 
advanced solid tumors (50% melanoma), were intravenously weekly administered for 
three consecutive weeks during a 28-day cycle [208]. Dose limiting toxicities were 
thrombocytopenia and fatigue. The pharmacokinetic profile of conjugated CPT showed 
rapid urinary excretion, and similar terminal half-life than free drug. 25 patients were 
assessable for response, but no objective responses (complete or partial) were noted. 
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Only 3 patients had stable disease, one breast cancer patient, one histiocytoma and one 
melanoma, whereas the rest exhibited progression of the disease. Overall, this trial 
provided a strong indication that CT-2106 may have the ability to substantially improve 
the toxicity profile of standard CPT. 
XMT-1001 is a water soluble macromolecular conjugate (Mw~70 kDa) synthesized by 
tethering CPT by hydroxyl group at C20 position to a hydrophilic, biodegradable 
polyacetal polymer, poly(1-hydroxymethylethylene hydroxymethylformal), also called 
PHF or Fleximer® [209]. This compound was designed to improve efficacy and toxicity 
with regards to CPT, and showed higher antitumor efficacy compared with irinotecan 
against HT-29 human colon carcinoma xenografts [210]. CPT discharge involves a dual-
step release mechanism: first, XMT-1001 follows an intramolecular transacylation 
releasing two CPT prodrugs, camptothecin-20-O-(N-succinimidoglycinate) (CPT-SI) and 
camptothecin-20-O-(N-succinami-doyl-glycinate) (CPT-SA) and, then, these prodrugs 
hydrolyze to yield CPT. A Phase I study with XMT-1001 was lauched in 2007 by Mersana 
Therapeutics, Inc. to determine the maximum tolerable dose (MTD), and to assess the 
safety and pharmacokinetics of XMT-1001 and its release products. Then, a total of 24 
patients with small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) 
received XMT-1001 by intravenous infusion every 21 days [211]. No drug related serious 
adverse events were observed during treatment, whereas several patients showed 
promising evidence of clinical activity, including tumor shrinkage and stable disease for 
several weeks. Also, preliminary pharmacokinetics findings confirm the formation of 
release products (CPT-SI, CPT-SA, and CPT) in plasma. Subsequently, a Phase Ib 
extension study of XMT-1001 was initiated in 2011 over 11 patients (10 with NSCLC and 
1 with gastric cancer), aiming at fully exploring the broad anti-tumor potential of this 
formulation, but no further results have been reported yet. 
 
Table 2. Nanomedicines of CPT under clinical investigation.a 
Compound Formulation Clinical trial 
Number of 
patients Pathology Dosis regimen MTD
b Toxicity Ref. 
CRLX-101 Cyclodextrin-PEG copolymer Phase Ia 10 
Advanced Gastric, 
Gastroesophageal, or 
Esophageal Squamous or 
Adenocarcinoma 
60 minute IV infusions on 
days 1, 8, and 15 of a 28 
day cycle 
30 mg/m2/month Pancytopenia [202] 
  Phase Ib/IIa 62 Solid malignances 
60 min IV infusion for 3 
consecutive weeks every 
28 days 
15 mg/m2 IV every 
2 wks 
Myelosuppression, 
grade 3/4 neutropenia 
and fatigue. 
[203] 
  Phase II 29 
              Ovarian Cancer 
Fallopian Tube Cancer 
Primary Peritoneal Cancer 
IV infusion once every 14 
days. Each cycle is 28 
days 
15 mg/m2 IV every 
2 wks 
G3 vasovagal reaction 
G3 pneumonia G3 
pulmonary embolism 
[117] 
  Phase II 157 Non-small cell lung cancer 15mg/m
2 IV every other 
week 




CT-2106 Poly(L-glutamic acid) polymer conjugate Phase I 24 Adult solid tumors 







grade 2 hematuria, 
stomatitis 
[207] 
  Phase I 26 Advanced solid tumors (50% melanoma) 
10 min IV infusion weekly 
x 3 every 4 wks 
25 mg CPT-
2106/m2/week 
Grade 3 fatigue and 
grade 3 and 4 
thrombocytopenia, 






Phase I 24 Small and non-small cell lung cancer 
1-20.5 mg CPT eq/m2 IV 
infusión once every 3 wks 




  Phase Ib 11 
10 with non-small cell lung 
cancer and 1 with gastric 
cancer 
IV infusion once every 3 
wks 
initially 113 mg 
CPT (eq)/m2 --- [209] 
EZ-246 Pegylated CPT conjugate Phase I 37 Solid malignances (15 with colorectal cancer) 






bladder toxicity at 
4800 mg/m2 
[213] 
  Phase II 35 
Advanced and metastatic 
adenocarcinomas of the 
stomach gastroesophageal 
junction 
1 h IV infusion once every 






MAG-CPT N-(hydroxypropyl)methacrylamide polymer Phase I 23 
Metastatic, refractory solid 
tumors (6 with colorectal 
cancer) 









a Additional information may be found at www.clinicaltrials.gov. 
b MTD: Maximun tolerated dose 
Conversely, EZ-246 (also known as pegamotecan) is a covalent conjugate of CPT with 
poly(ethylene glycol) (Mw~40 kDa), developed by Enzon Pharmaceuticals. In preclinical 
in vivo studies, this compound showed higher activity than irinotecan and topotecan 
against human tumor xenografts (including colon, lung, breast and pancreatic origin) 
[212]. Then, in a Phase I trial of this formulation, 37 patients with different solid 
malignancies (15 with colorectal cancer) were administered by intravenous infusion for 
1 h every 3 weeks. Antineoplastic activity was observed in 2 patients, but significant 
toxicity was associated to the treatment, mostly neutropenia and genitourinary toxicity 
[213]. Actually, free CPT accumulated slowly in plasma, with a dose proportional 
pharmacokinetics, which forced to reduce the dose limiting toxicity in 6 patients. 
Subsequently, a Phase II trial was started at 2004 over 35 patients with advanced and 
metastatic adenocarcinomas of the stomach and gastroesophageal junction [214-215]. 
Partial antitumor response was observed in 5 subjects, with a median time to progression 
of about 12 weeks, and median overall survival of 38 weeks. However, severe toxicity, 
including neutropenia, thrombocytopenia, fatigue, nausea, vomiting and anorexia, 
appeared again in some patients, showing the need of further studies, maybe combined 
with other active agents.  
Finally, MAG-CPT (also known as PNU 166148 and mureletecan) comprises CPT linked 
to a water-soluble polymeric backbone methacryloylglycynamide (Mw~18 kDa), 
developed by Pharmacia. Therefore, CPT derivatives were synthetized by conjugation 
of a N-(2-hydroxypropyl)methacrylamide copolymer precursor with modified CPT at the 
C20 α-hydroxy with glycine [216]. These conjugates were designed primarily to improve 
the clinical delivery of CPT, and utilized a hydrolytically labile spacer able to liberate drug 
intratumourally in a pH and enzyme-dependant manner. Preclinical studies of MAG-CPT 
showed that this compound was active in colon, stomach, pancreas, ovary, breast, lung, 
and melanoma xenograft models [217]. Then, a Phase I study over 23 patients with 





[218]. Unfortunately, no objective antitumor responses were seen, and severe drug-
related toxicity effects were reported, as myelosuppression, neutropenic sepsis and 
diarrhea. Also, one patient died after the first treatment cycle at the maximum dose. 
Based on the results of the Phase I studies and the intratumoural kinetic study, 
Pharmacia made a strategic decision to discontinue further clinical development of MAG-
CPT [219]. 
 
6. Conclusion and future directions 
CPT is one of the most active molecules for cancer treatment, but its particular limitations 
as poor solubility, lack of stability of the lactone ring and strong toxicity, have encouraged 
the development of different delivery forms in order to achieve a safe approach. Here, it 
is a fact that current cancer treatment cannot be tackled as the administration of a single 
therapeutic molecule but, instead, the new target is personalized medicine, which selects 
the appropriate drug combination and dosing schedules for individual patients.  
In this context, despite the fact that irinotecan and topotecan present improved 
pharmacokinetic parameters, and that they are the only commercial CPT derivatives 
approved by the FDA, therapies merely relying on single, small molecules seem now out 
of step, mostly due to their limited efficacy and unacceptable toxicities. For this reason, 
huge emphasis is being placed on developing new DDSs which are able to 
simultaneously deliver CPT and other active agents, as well as incorporating imaging 
moieties that may ease the diagnosis process. Most specifically, future seems good for 
those systems which are able to selectively discharge the drug at the target cells under 
an specific stimulus, with no previous release. Stimuli-responsive preparations provide 
a dramatically better spatial and temporal control over drug release, which is crucial for 





Although no CPT nanomedicine has achieved commercial form, there are several 
organic polymer compositions currently under different phases of clinical trials. In all 
cases, there is a significant increase of the MTD with regards to CPT structural 
derivatives. Among them, cyclodextrin conjugates as CRLX101 seem to be the best 
positioned to achieve regular clinical use, according to the promising efficacy and 
tolerability results, as well as plasma half-life values obtained in Phase II trials. However, 
most of these systems show limited functionalization ability to bind covalently the drug, 
which limits the loading capacity, as well as the possibility to combine CPT with other 
therapeutic molecules and/or imaging agents. In this sense, next generation of CPT 
delivery vehicles should merge properties of organic and inorganic materials. Whilst 
organic components will provide good stability in physiological fluids, low toxicity and 
immunogenicity, and minimized reactions with serum proteins, inorganic materials 
(which alone could present strong limitations for biological use, due to possible 
compositional toxicity and severe interaction with serum proteins), may offer almost 
unlimited external surface area to bind different active molecules and stimuli-sensitive 
linkers and devices. Obviously, from the regulatory point of view it is much more 
challenging to develop hybrid nanocarriers, which require the evaluation of every single 
component and, possibly, their clinical translation will not be as smooth as that of organic 
polymers, but the potential of these systems points out to solving the strong interpatient 
variability that currently hampers the widespread use of CPT nanopreparations. In this 
review, we have tried to reflect some of the most interesting candidates to achieve the 
clinics soon.  
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